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INTRODUCTION 
Hospital drug expenditures have increased dramatJcally 
/ over the last fifteen years. I 
-) one billion dollars for drugs. 
In 1972, hospitals allocated 
That figure had risen to 
(~ t·.hree billion dollars by 1982, a 300% increase (1). Part 
of this inflation in drug expenditures haM been due to 
a number of factors, including increased number of 
hospital patient days, increaseJ average drug expenditure 
per patient and increased cost of drugs. At the ~arne time, 
inno"l..-ations in the various antibiotic therapeutic 
categories have resulted in new and rel2tively expensive 
antibiotics being introduced into the market almost every 
year (2). This has resulted in an increase in antibiotic 
use which adds to drug expenditures. 
The increased use of antibiotic therapy over the last few 
decades has led to a number of problems for the health 
care .delivery system. These include bacterial resistance 
to the current antJbiotics with a con~omitant increase in 
thH cost of health care. Attempts have been made to 
contain the use and cost of antibiotic therapy through 
drug utilization review and the implementation of c1r1sed 
formulary systems (3). There have also been attempts made 
to contain the overall cost of health care through 
innovative financing m0chanisms which offer an incentive 
l 
to optimize quality while minimizing the cost. Included 
among these financing mechanisms is a system of Diagnosis 
Related Groups (DRG's), currently being utilized by 
Medicare. The rationale behind DRG's is to offer a fixed 
level of reimbursement based on the patient's primary 
diagnosis as ~Hll as a nu1uber of other patient variables. 
It is incumbent upon the-hospital to keep the cost of 
tr~ating these Medicare patients below this f~xed level, 
dictated by DRG's, in order to earn a profit (or to avoid 
a loss). This system of reimbursement is vastly different 
from the fen-for-service method which tends to encourage 
over-utilization of health services. In order to cope with 
the DRG system of reimbursement, a number of different 
strategies have been considered by pharmacy departments. 
Among these are competitive bidding, strict enforcement of 
drug formularies clnd 
cost-benefit aspects 
physician education regarding the 
of drug therapy. The process of 
accepting a drug onto a hospital formulary has shifted 
fr0m marketing and promotion to rationaliz~tion on the 
basis of its efficacy, safe~y and cost. The adv~nt of 
computerized systems within the hospital pharmacy allows 
the pharmacist to evaluate expensive drug products in 
terms of their efficacy. 
Among the mdjor therapeutic categories within the ge11~ral 
classification of antibiotics, r:ephalosporins have had a 
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significant impact on health care costs. Since the 
cephalosporins were first introduced, they have accounted 
for an increasing proportion of the hospital drug budget. 
Presently, 
hospitals 
a8out SO% of the avera~e drug budget in 
is allocated to cephalosporins (4,5). In 1983, 
:;ei ox l-ri•n----=a--nc-.1d--e-e-£anra-n--ti-o-l---e~~. -a--rdce-d-f-i-r-s-t---a-n-cl--s-e-c on d.-.,,---------
respectively, among all cephalosporins in terms of dollars 
spent (6). 
T~1e primary purpose of this study is to analyze the 
form u 1 a r y status of c e ph a 1 o s pori n s am_, n g a representative 
·sample of hospitals in the United States. In addition, 
'the research design attempts to determine the ranking of 
:cephalosporins in terms of acceptance to the hospitals' 
formulary :-tnd actual stocking of the cephalosporin 
p r o d · t c t s . The s t u d y w i 11 at t em p t t o a ~,: c e ·c t a in the r e a s on ~: 
for these rankings and the influence of DRG implem2nta-
tion, teaching status and hospital bedsize on number of 
cephalosporins on formulary and in stock. This may yield 
insight into the strategies that hospitals are currently 
using to contain a significant pro?ortion of their budget 
for pharmaceutical products. 
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PHARMACY ECONOMICS, DRGS AND INFECTIOUS DISEASES 
The hospital ph~rmacy budget is generally comprised of two 
parts: salaries (approximatively 30%) and drugs 
(approximatively 60%). Antibiotics are the major component 
of the hospital drug budget (7). As many as 35% of all in-
patients receive an antibiotic du1·ing their hospital stay 
(8). Eight cephalosporins were among the top twenty 
hospital products in terms of dollar sales in 198'1 (see 
Table 1) :laking cephalosporins the largest therapeutic 
category within the antibiotic budget. Oral and parenteral 
~ephalosporins account for approximately half of the 
~ntihiotic pharmacy budget. With the ongoing development 
•of new antibiotics, a number of problems have emerged. 
Among these are the escalation of health care expe~ditures 
and the frequency of superinfections. As a result of the 
increase in health care expenditures, the pharmacy 
profession is confronted with new challenges. It is 
incumbent upo~ pharmacists to decrease the overall co~t of 
drug therapy while maintaining t1~e quality of care. 
TABLE 1 
TOP-SELLING CEPHALOSPORINS PRODUCTS IN HOSPITALS 
FOR 1983 
!--------------!--------------!-----------! 
! GENERIC NAME ! TRADE NAME RANKING 
!--------------!--------------!-----------! 
CEFOXITIN MEFOXIN 1 
CEFAMANDOLE MANJOL 2 
CEFAZOLIN ANCEF 6 
CEFOTAXIME CLAFORAN 7 
4 
TABLE 1 (CONT.) 
TOP-SELLING CEPHALOSPORINS PRODUCTS IN HOSPITALS 
FOR 198:~ 
MOXALACTAM MOXAM 11 
CEFAZOLIN KEFZOL 12 
CEFOPERAZONE CEFOBID 13 
CEPHALOTHIN KEFLIN ! 15 
!--------------!--------------l-----------1 
source: BARRIERE S.L.-Cost-Containment of Antimicrobia; 
~------~_Thera QJ._·- lJ rug In t--e-i_l_i_g_e_n-ce_a_n_d-----(.l_Ji.--n--i-ccd-Plra-rnm-c-y--,-l-9--,l-9-8-§--.,-------
pp.278-281. 
\Hth increases in health expenditures, third-party 
programs have be~ome engaged in innovative mechanisms to 
control the cost of health care. Diagnosis~Related Groups 
(DRGs) .a·re ind.icative of this new attitude. Inglehart 
review~~d/' the different steps prior to the implementation 
of DRG'.s · (9). Attempts by the Carter Administration to 
impose h o spit a 1 cost 1:: on t r o 1 in 19 7 7 did not meet with 
success. Section 223, enacted originally as part of the 
Social Security Amendment in 1972, was initially dLrected 
to 1 i m i t i: he p e r d 1. em p a y !ll en t f or h o s pi t a 1 c o s t s • :: h e 
Omnibus Budget Reconciliation Act of 1981 tightenPd 
sectL1n 223 amendments but was still limit:ed to routine 
costs. In 1983, the Congress vot~d the system of 
pr-ospective reimburs0ment (called D '. a g 11 o s j_ s Related 
Groups) and it was decided that this amendment shou~d he 
:i. m p 1 em e 11 ted over t . .he fisc a 1 years 1 9 8 4 -·1 9 8 7 (l 0) • 
TABLE 2 
IMPLEMENTATION OF DRGS 
!------------!-----------!------------!----------! 
! FISCAL ! REGIONAL ! HISTORICAL ! NATIONAL ! 
YEAR ! RATE ! COSTS ! RATE 
!------------!-----------!------------!----------! 
! 1984 ! 25% DRG ! 75% DRG ! 0% DRG ! 
!------------!-----------!------------!----------! 
! 1985 ! 37.5% DRG ! 50% DRG ! 12.5% DRG! 
!------------!------------!------------!----------! 
1986 37.5% DRG ! 25% DRG 37.5% DRG! 
1987 0% DRG 0% DRG 100% DRG ! 
!-------------!-----------!------------!----------! 
>~Histori.cal CCists: drawn from the target rate provision~: 
outlined in the Tax Equity and Fiscal Responsability Act 
(TEFRA) 1972. 
source: ENRIGHT S.M.Understanding Prospectiv~ Pricing an~­
DRG's. American Journal of Hospital Pharmacy;4:1493-1494, 
198r 
The new sectio~ 223 extends the limits to special care, 
operating costs and <1ncillary services (e.g. phannacy 
services). The limits are on the basis of cost per 
discharge. These limits are not applicable to children's 
hospitals, long-term care hospitals, and rural hospitals 
with fewer th~n 50 beds. 
The prospective payment system involves prepayment for 
servlces according to that patient's DRG. A patient may be 
placed in one of 467 existing DRGs which are defined by 5 
different variables :11). 
These are: 
1) primary diagno~is, 
2) secondHry diagnosis (comorbidity), 
6 
3) age, 
4) sex, 
5) d i ::; c h a r g e status, 
6) operating room procedures. 
Hospitals may keep the difference between the f i.xed DRG 
payment rate and their actual costs for treating Medicare 
patients. 
minimize 
Therefore, the finan:ial incentive is to 
the use of ancillary ser ·!ices~- This · cost 
containment system was not developed to decrease the 
quality 'Of ca.::>: e but rather to stimulate the reevalua t.~.on 
of ancil1ar·y services . The inf 1 ues,ce of DRG's forces 
health -'care professionals to reevaluate tht' average cost 
of drugH ~sed per DRG as well as to stimulate competitive 
bidding j_n hospitals. Curtis reviewed the different 
mana~ement strategies developed in order to cope with th~ 
new reimbursement system (12). These strategies focus on 
the drug product, cost of storage a~td the prescriber. 
Economies in the pharmacy department may be achievHd 
through voJ.ume purchasing, cash paym~nt and group 
purchasing. Bid contract~: have the potential of 
signi -~icantly reducing the ho~;pital' s overall 
pharmaceutical budget. Antibiotics are many times subject 
to bid contracts. This is particularly true of Lirst 
generatio11 cephalosporins. Bid contracts may be signed for 
7 
one product marketed by two different companies (e.g. 
Cefazolin) or two products which are considered to be 
therapeutic equiva.lents (e.g. Cephalothin and Cefazolin). 
The implementation of a closed formulary inay facilitate 
the objecLive of decreased rlrug inv~ntory through periodic 
r e eva 1: ITHL.tun----u-£----e--a-c-h~d-r-u-g~b-a-s-e-d~u-pe-n--i-t-s-e-f-f-i-t-.a-G-}L______fl.-R-d.-------
cost. The restriction of open prescribing has been shown 
to be both cost effective and to improve the quality of 
care (13,--16). A number of strategies are available for 
restricting the prescribing patterns of physicians. These 
include ~r±tten request and control of antibiotic release 
by the · : in f e c t i o us d i s e a s e s e r vi c t' an d I o r pha,:macy 
department:. 
The advent of DRG's has prompted hospital pharmac~es to 
restrict their formularies in order to control inventory 
costs. Antibiotics are the primary focus of the Pharm~cy 
and Therapeutic (P&T) Committ;·es due to their wide 
utilization, high costs and misuses (17-19). In 1970, 
Scheckler and Dennett reported that no clear indication 
was found in 
therapy (20). 
60% of patients recPiving antimicrobial 
Approximatively JS% of all infants and 
children admitted to hospitals receive antibiotics some 
time during their hospital stay (21). The rationale for 
their use is not always clear and the duration oE th~rapy 
8 
is oftentimes exc~ssive. Durbin et al., studied the 
impact of a new system incorporating the rationale for 
each antibiotic prescribed in a general hospital (22). 
They reported that the most important effect of this 
system was on prophylactic surgery where th<~ mean duration 
for surgical )rophylaxis dropped fr0m 4.9 days to 2.9 
days. In addition, the percentage of patients receiving 
surgical p~ophylaxis for more than 2 days was reduced by 
half. Hayman and Sbravati rep)rted on the effectiveness of 
controllins usage of cephalosporin~ and aminoglycosides. 
Second generation cephalosporin utilization was reduced by 
52% while first generation usage increased by 48%. The 
average cephalosporin cost per dose decreased from $5.85 
to $4.94. The shift towards an increased use of first 
generation cephalosporins and the restriction on the 
prescribi~tg of aminoglycosides resulted in the savings of 
$200,000. Little change was reported in the total number 
of antibiotic doses dispensed during the study period 
(2.3). 
Programs of formulary control have been implemented in 
man; hospitals (2L+,25). Infectious disease specialists 
frequently achieve their goal of rational drug therapy 
through control of the approval process. Eowever, in the 
case of community h_,spitals, 
office-based and, thf:refore, 
9 
physicians ace normally 
have a difficult time 
allowing another health professional to cor:trol their 
prescribing patterns.(26) 
Information is necessary to ensure that therapeutic agents 
are userl appropriately by physicians. There are numerous 
ways of providing this information. These include 
demonstrated that a newsletter can b~ an effective tool in 
altering prescribing habits over a period of three months 
while inservice education was relatively 
ineffective. They concluded that deletion from the 
A formulary was still the most appropriate method for 
controlling the use of antibiotics (27). 
Drug utilization review employs a different approach to 
dosage, length of treatment and alternative ther,apy of 
antibiotic usage. Hetaway and Barriere found that DUR 
mostly involves aminoglycosides (38%), cephalosporins 
(35%) and penicillins (10%). Drug utilization reviews are 
generally divided into three different approaches; 
retrospective, concurrent and prospective. A retrospective 
DUR helps to define areas where f!ducation is needed while 
concurrent DUR is helpful in avoiding drug interactions 
and iatrogenic disease. Prospective DUR studies alternate 
therapy by taking into account cost factors and evaluating 
ancillary services such as drug assays (28). 
10 
FORMULARY ACCEPTANCE OF ANTIBIOTICS/CEPHALOSPORINS 
A formulary attempts to establish a compilation of drugs 
for the medical staff without therapeutic duplication at 
the lowest possible cost(29). The American Society of 
Hospital Pharmacists (A.S.H.P.) has set guidelines for 
establlshing a formulary. 
be ap)roved by the medical staff and then the Pharmacy and 
Therapeutics ' Committee is or ganL~ed. The minimum 
membership of this commit~ee is three physicians, a nurse, 
a pharmacist and an administrator. Their respnnsibilities 
include evaluation of new drugs and educational 
< a c.t i vi t.i e s • Dr u g s a r e t y p i c a 11 y cons i d e r e d a c c o r d in g to 
... their chemical (versus trade) name during the acceptance 
process. 
procedures 
situations. 
available, 
consid~red. 
Non-formulary drugs normally have explicit 
indicating how to obtain them for unique 
Because of the large number of drugs 
both effectivenesH and cost of therapy are 
It is this committee which decides wh~ther 
drug ure admitte~ or deleted from the hospital formulary 
(30). 
Once a drug product is ac•epted, selection of a .specific 
vendor is conducted by t 1~ e Ph a:·:· mac y De par \·.men t • Criter-ia 
for drug procurement are summarized in Table 3. These 
criteria may be used to optimize the hospital's formulary. 
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TABLE 3 
CRITERIA FOR DRUG PROCUREMENT 
!-----~--------------------------------------------! 
! 
! B i \)a v a i 1 i b i 1 it y 
! 
! 
!Cost 
!M8nufacturer's past record 
!of producing quality products 
Availibity on a 
reliable basis 
Demand I Usage 
!--------------------------------------------------! 
source: KELLY W.N., BENDER F.H.-Implementi~ and Maintain-: 
i r:!.& .9. · V i a 1U- e F o r .!E u 1 ~U-, H o s p i t a 1 F o r m u 1 a r y , V o 1 u me 
l8,1983,pp.976-987. 
~· Antibiotics (particularly ce~halosporins) are frequently 
·~ reviewe~ because of their high cost and potential mi~:~ses 
which have have be0n reported to be as much as 87% (31). 
Furthermore, new cephalosporin antibiotics are constantly 
being marketed. The admission criteria for cephalosporins 
and other antimicrobials traditionally have been based 
upon spectrum of activity. Because oE the availability of 
numerous thernpeutic <! q u i v a 1 en t s a s well as 
implementation of new reimbursement systems, a number of 
other issues have recently arisen. Among these issues are 
host-bacteria interaction, pharmacokinetics and the 
overall cost. of antibiotic therapy (32). 
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Criteria for admission onto the formulary may depend on 
the type of institution considered as well as tl;e ·1 rug 
itself. The mix of drug products appears to be dHpendent 
upon the type of institution. For example, the formulary 
of a maternity hospital will likely be different tha:t that 
J-------------.o~ a p-s~y-c-h-i.----a--t-l-i'---h--o-s-p-i-t:-a-1--( 3--3-j-.--1-e-a-e-R-i-R-g-B.-e-s-p-i-t-a-l--£-~-a-y'--------------
also differ from their non-teaching counterparts in terms 
of the makeu~ of their formularies. There are a number of 
attitudes that may predominate in the case of teaching 
hospitals. These inc1.ude the need to provide a broad 
2: exposure 0f drug therapy to medical reside~ts and the ~eed 
~~ to ~each rational drug prescribing habits. 
·~ There are specific factors which need to be addressed 
prior to a d1·ug's acceptance onto a formulary(34,35). They 
are as follows: 
_§~_s:__ific Indications: 
The mdin indications for which the drug has bee~ F.D.A. 
approved need to be mentioned in view of its formulary 
acceptance. 
~ c t rum of_ Action ( see Tab 1 e 4) : 
In the case of antibiotics, the MIC-90 ( conce~tration of 
antibiotic required to inhibit growth of 90% of a pool of 
clinical isolates of a particular bacterial species ) must 
be indicated for the major organisms encountered in the 
13 
clinical setting.· The notion of ger,eration for 
cephalosporins has been defined on the basis of activity 
ag.o-iinst gram negative organisms. Tables 5, 6 and 7 list 
cephalosporin antibiotics by generation. 
The first gen~ration cep~alosporins are mainly active 
against gram positive organisms. The chief shortcoming is 
a la:k of activity against most gram negative b~cilli and 
the anaerobic rod Bacteroides fragilis (35). 
The classical pattern of second generation cephalosporins 
has been a more extended spectrum against gr~m negative 
b. spe·cies including Haemophilus inf.Iuenzae, Enterobacter 
Proteus m~rabilis, and Neisseria 
-- ----·~-----
~h Cefuroxime has a similar spectrum of activity as does 
Cefamandole Rgainst gram negative bacilli but is less 
active against gram positive organisms ( 3 6) • Tht~ ne ;.ver 
second generation Cefonicid and Ceforanide, have been 
shown to have an irregular activity against gram positive 
organisms (37,38). Cefoxitin must be considered apart from 
the other second generation cephalosporins. It possesses 
the highest activity against Bacteroides fragilis and is 
considered the crug of cho~ce in cases of anaerobic 
infections (39). 
The third generation cephalosporins exhibit their best 
activity against gram negative bacilli i.ncluding Esherichia 
coli, Klebsiella J2Eeumoniae, Enterobi=~cter ~ Proteus 
14 
mirabilis, frovidencia ~ (40). The a1.ti-pseudomonal 
activity of the third generation cephalosporins differs 
according to the drug considered. C e f o p e r a z •) n e , 
Ceftazidime and Moxalactam have been reported to be 
effective against Pseudomonas aeruginosa(41). However, 
the s e p r o d u c t s a r e n o t c on s i. d-er·t:d-----rh-e--d-n:r-g-o-f-e-h-e-i-e-e---f-e-rc------------
pseudomonal infections. 
Enterococc~ (Streptoccus faecali~), Listeria ~~ and 
Legionella ·~~- (42) are not adequately covered ty 
~ephalosporins (all three gen~rations considered). Open 
t r i a 1 s are e x t r em e 1 y d i f f i c u 1 t t o in t e r p r e t b e c au ·; e of 
variation of pathogens and severity of illness. Any review 
'\ of the primary lit~rature should in~lude controlled 
trials. 
Pharmacokinetics: 
The pharmacokinetic information for each drug must include 
half-life, protein binding, and pathway of excretion. The 
importance of half-life allied with MIC-90 is increasingly 
emphasized with the newer cephalosporins. Ceforanide has a 
half-life of 3 hours, Cefonicid has a half-life of 4.5 
hours and Ceftri.axone h·:S a half-life of 7 hours (43-45). 
These long half-lives in combination with effective 
MIC90's at 12 hours for Cefonicid and 2~. hours for 
Ceforanide and Ceftriaxone influence the dosing interval. 
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A biliary excretion pathway is a parameter to consider in 
cases of patients with impaired renal function or 
infections of the biliary tract. Only Ceftriaxone and 
Cefoperazone have significant biliary excretion among the 
cephalosporins (46). 
Adverse ~ reactions: 
It is necessary to evaluate therapeutic advantages over 
adverse drug reactions. The safety profil~ of 
cephalosporins is oftentimes such that formulary 
1 dec~sinns CEnnot be based upon this issue. In the case of 
Ceftriaxone therapy , the frequency of diarrhea has been 
reported 
reported 
as high as 40% (47). Coagulopathies have 
with Hoxalactam and ·less frequently 
Cefoperazone and Cefamandole (48). 
Contraj.ndications anciprecautions: 
been 
with 
Because of high leyels of toxicity, drugs might be 
restricted to certain types of patients. Classically, 
cephalosporins are considered to be drugs with a low level 
of toxicity. In cases of renal impairment, the only 
recommendation for cephalosporins is a dosage adjustment 
with respect to the creatinine clearance in cases of renal 
impairment. This restriction is applicable to 
cephalosporins whose major route of excretion is via the 
1.6 
kidneys • 
Major~ interaction(s): 
Sign if i can. t interactions with the 111 o s t f r e q u ~~ n t 1 y used 
drugs might be a limitation of the usefulness of th~ new 
drugs. In the case of cephalosporins, this limitation does 
Frequency of administration is ~n important · factor to 
consider for the evaluatioL of the cost of a particular 
drug'·s therap.y. The recoDmended dosagBs should be 
specified fJr children, adults, cases of renal and hepatic 
\ insu£ficiency, and life threatening situations. 
First generation cephalosporins are considered therapeu-
t i c a 11 y e q tli v a 1 en t . Only their dosing intervals differ. 
Cefazolin is the only first generation cephalosporin which 
can be given every 8 hours. 
The second generation cephalosporins are 
heterogeneous. The rr~wer second generation cephalosporins 
with their long dosing intervals (every 12 to 24 hours) 
have been demonstrated to be useful in surgical 
prophylaxis and may be competitiv~ with Cefazolin for 
posit L> n on t h r:; h o spit a 1 f · ;r m u 1 a r y • So:ae of the newer 
second g~nerBtion cephalosporins have suffered from 
reports regarding poor coverage of Staphylococcus aureus 
1 7 
(50,51). 
Cefamandole and Cefuroxime have identical spectrum with 
the exceptiJn of activity on gram positi~e organisms. 
CefuroxLme has a better pharmacokinetic profile (penetra-
tion in the cerebrospinal fluid and long half-life), with 
recent marketing of Cefotetan, Cefoxitin nay also be 
subject to further scrutiny because both drugs have the 
same spectrum of activity with different dosing intervals. 
Cefotetan can be a1ninistered evert 12 hours whereas 
Cefoxitin should be administered every 6 hours (52). 
Cefotaxime· hBs been promoted on the basis of an 8 0r 12 
hour dosing interval. However, because of its 
pharmacokinetic properties, Cefotaxime is now used mostly 
at a dosage level of 2 grams every 6 hours. On the other 
hand, Ceftizoxime with an identi.cal spectrum of coverage 
and better pharmacokinetic profile, allows an 8-hour 
dosing regimen even in cases of life threatening 
situations. Cefoperazono and Ceftrjaxone with interval 
dosing of 12 hours and 24 hours, respectively, make them 
attractive cephalosporins for many hospitals' formularies 
( 49 ~ .. 
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Availability .2.f the product: 
At some institutions, packaging of the products is an 
important attribui·.e. A unit do:..:e distribuU.on system may 
provide a g •Od system of quality control as wel.l as a 
high level of safety. Baxter-Travenol has recently 
introduced a premixed frozen antibiotic system which has 
the potential to save labor cost. The time that is .saved 
by this typ~ of system may be us~d to provide an improved 
level of clinical services (53). 
Cost: 
Cost-benefit analyses are needed to include ne·,·: drugs onto 
f 1 • (,.I ) . ormu ar1es ~~ • Antibiotic c ·3ts can be reduced if the 
~i number o.f doses per· day can be safely redu-:ed. This has 
prompted F.D.A. approval for cephalosporins with long 
half-lives. 
TABLE 4 
COST OF THERAPY FOR THE FIRST 
GENERATION CEPHALOSPORINS 
!-------------!--------!-------------!------------! 
! NAME ! $/ GM TOT 1). :, COST TOTAL COST 
! PER DAY ! PER DAY 
! USUAL DOSES! MAX.DOSES 
!--------------!--------!-------------!------------! 
!CEPHALOTHIN ! $2.88 ! $51.52/ ! $94.56 ! 
1GM Q6H. 2~M Q4H 
!~------------!--------!-------------!------------! 
!CEPHAPIRIN ! $3.55 ! $54.20/ ! $102.60 ! 
! ! 1GM Q6H ! 2GM Q4H 
!-------------!--------!-------------!------------! 
!CEFAZOLIN $6.55 ! $49.65 $92.40 ! 
! ! 1 G ~1 Q 8 H • ! 2 G H Q 6 H • ! 
!--------~----!--------!-------------!------------! 
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TABLE 5 
COST OF THERAPY FOR SECOND GENERATION CEP~ALOSPORINS 
!-------------!--------!-------------!------------! 
NAME ! $/GM ! TOTAL COST ! 'l'OTAL COST ! 
! ! PER DAY ! PER DAY 
! ! USUAL DOSES! MAX.DOSES 
!-------------!--------!-------------!------------! 
!CEFAMANDOLE $7.15 ! $61.45/ $145.80/ ! 
! ! 1GM Q6H. 2GM Q4H 
!-------------!--------!-------------!------------! 
!CEFUROXIME $7.85 ! $47.67/ $87.12/ 
o--;-~-s-~~;---~8-H-!-l--;-5-G-I·1-~-6-H-!--------
!-------------!--------!-------------!------------! 
!CEFONICID ! $15.20! $25.20/ $50.40/ 
! ! 1GM Q24H ! 2GM Q24H ! 
!-------------!--------!-------------!------------! 
!CEFORANIDE' $9.95 ! $29.90/ $39·.90/ · ! 
! ! O.SGM 12H ! 1GM Q12H 
!-------------!--------!-------------!------------! 
!CE?OXITI~ ! $8.49 ! $73.96/ ! $161.88/ ! 
! ! ! 1 GM Q6H ! 2GM Q4H ! 
'~ !-------------!--------!-------------!------------! 
TABLE 6 
,··:·-:.: C{)S·T O·-F. 'fliE.R·APY FOR THIRD GENERATION ·:~EPHALOSPORINS 
! --------------! ---------! ---------.----! ------------! 
NAME ! $/GM ! TOTAL COST ! TOTAL COST ! 
! ! PER DAY ! PER DAY 
! USUAL DOSES! MAX.DUSES 
!-------------!--------!-------------!------ ------! 
l CEFOTAXIME ! $l1.45 ! $85.80/ ! $197.40/ ! 
! ! 1GM Q6H. ! 2GM Q4H. ! 
!-------------!--------!-------------!------------! 
! CEF'L'IZOXIHE ! $L1.18 ! $63.54/ ! $129.44/ 
! 1GM Q8H 2GM Q6H. ! 
!-------------!--------!-------------!------------! 
! CEFOPERAZONE! $12.20 ! t66.60/ ! $1/5.36/ 
! . ! 1 GM Q8H ! 3GM Q6H. ! 
!---------·----!--------!-------------!------------! 
! CEFTRIAXONE ! $25.12 ! $25.12/ $125.36/ 
! ! 1GM Q24H 2GM Q12H.! 
!-------------!--------!-------------!---------~--! 
MOXALACTAM ! $12.20 ! $66.60/ $186.40/ 
! ! 1 GM Q8H ! 3GN Q6H. ! 
!-------------!--------!-------------!------------! 
1984-1985 American Drugg·i.st Blue Book Average Wh_,lesale 
Price. 
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According to Barriere, open formularies are not 
appropriate in today's health care enviro1.ment. The trend 
is to limit duplication for the purpose of minimizing 
cost. Due to the cost of I.V. preparation, the concept of 
single dose therapy is attractive from a cost standpoint. 
I. v. preparation can range from 35-75% of the total cost 
of the drug.therapy (54), 
Previously, teaching status and bedsize have bee~ used to 
explain differences i.n hospital costs. The imp lemen ta i· ·i:on 
of DRG's creates a method to evaluate the quality of care 
and,, u. t.il i·z at i.o n of services in most hospitals. Three 
~~ areas will be influenced by the implementation of DRG's 
(54): 
1. Le~gth of stay: great variability exists from one 
hospital to ~nother in t1e duration of antimicrobial 
therapy ( e • g • endocarditis antimicrobial therapy ranges 
from 2 to 6 weeks) 
2. Ancillary services: restricting the use of expen~ive 
drags and increased use of generic equivalents will be 
considered. A more homogeneous attitude towards drugs will 
be achieved only if estimated duration of ant~microbial 
therapy is assessed. 
3 . Capital purchases: manufacturers will cor.centrate 01. 
areas which seek to decrease the total cost of therapy. 
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Sophisticated i·.echnologi.es will probably be modulated in 
their development. 
Already, formulary re:'valuations have taken place and will 
help in the control of hospital dru; budgets. Crane et al. 
reported savings projected for 1935-86 for cephalosporin 
decreased by 5.24% for first generation cephalosporins, 
11.31% for second generation cepha1osporins and 39.4% for 
~h~_rd generation cephalosporins (56). 
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RESEARCH OBJECTIVES 
The objeciives of the study are to determine the. formulary 
status of ce;halosporins, the reasons for their status and 
their levels of stocking in hospitals in the United 
States. These objectives will be accomplished by evaluat-
l n g UJ: e f o lllioY\Wvlliinll:g?.:· ------------------------------
1. The cephalosporins will be analyzed in terms of the 
levels of formulary approval. 
2. The non-formulary status of cephalosporins will be 
mi'a 1 y z e d in t e ·c m s o f t h o s e : 
-~~ot included on formulary through formal rejection 
-·· .:·no t inc 1 u d e d on form u 1 a r y 'vi t h a p 1 anne d review 
- not included o:r: formulary with no plans to review 
3. The stocking of cephalosporins in hospitals. 
DEFINITION OF TERMS 
1. Full Approval Status - the drug is not submitted to any 
kind of formulary restrictions 
2. Restricted Approval Status - the physician does not 
have ful1 power over the choice of drug i·.herapy; for 
example, a specific drug may not be US·~:! without. prior 
infectious di:3ease oc clinical phar,nacist consultation; 
further restrictions may he due to trial use of a particu-
lar dr·ug or the limitation of use to a specific diagnosis 
or infection. 
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3. Not ~Formulary Due !.2_ Formal Rejection - the drug is 
not admitted to the formulary as a result of deliberations 
of the Ph~rmacy and Therapeutic~ Committee. 
4 • N o t ~ F o r m u 1 a r y W i t h P 1 an s t o_ R e v i e w - tJ ~ e d r u g has 
not yet been accepted on the for~ulary; however, evalua-
tion of the drug for formulary review is s~heduled. 
5. 
has 
Not ~l Formulary With No Plan~ !Q Review - the 
not been accepted on the formulary; there are LO 
drug 
plans 
to review. 
6. Therapeutic Egui•alent - a drug product that is consid-
ered to be e~ual or .superior to other drugs within the 
same therapeutic category. 
HYPOTHESES 
The following research hypotheses guide this investiga-
.,,.,. tion. The first six hypotheses relate to the first object-
ive, to de·termine the formulary approval status of 
cephalosporins. 
There is a significant d i f f e r en :: ,.. in the formulary 
approvaL rate among t·.he thre.L~ genera t i _, n s of 
cephalosporins. 
Hypothesis 2: 
There is 
approval 
sporins. 
a significant difference in the restricted 
rat:~ among the three genera t io·;: s of c ep ha 1 o-
Hypothesis 3: 
The reasons for restricting cephalosporins are d~pendent 
upon the generation considered. 
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_Hypothesis !!_: 
Cephalosporins ad~~tted on formulary are dependeGt upon 
whether DRG's are in effect. 
l:!.YJ?.othesi~ 2 
Cephalosporins admitted on formulary are dependent upon 
the hospital's te~ching status. 
Hypothesis .fi 
Cephalosporins arlmitted or. formulary are dependent upon 
the hospital's bedsize. 
Hypotheses 7 through 13 relate to the s<:c.u;d objective. 
These hypotheses will determine whether non-fo~mulary 
status of cephalosporirrs and the concomitant reason(s) are 
the sara e f o r e a c h o f L he t h r e e g en 1 :rat .i. on s • 
Hypothesis. 7: 
There is a correlation between the date in which a 
cephalosporin enters the ma~ket and its formulary status. 
Hypothesis 8: 
There is a significant differenc~ in the rate of formal 
rejection among the three generations of cephalosporins. 
The reasons why cephalosporins are formally rejected vary 
based ~pon their generation. 
Hypothesis lQ 
There is a significant difference among the three genera-
tions of ~ephalosporins regarding the hospital's plans to 
review the ceph~losporins for formulary status. 
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Hypothesis .ll 
The expected outcome of non-formu1.ary cephalosporins which 
are scheduled for review is dep~ndent upon the generation 
of cephalosporins considered. 
!!.Y.J2.othesis 12 
There is a significar1t difference hased upon generation in 
the rate of cephalosporins that are non-formulary without 
any plans to review. 
There· is a significant differenc":! based ur,on generation 
for the reasons that cephalosporins are not accepted onto 
the formulary and why they do not have :t planned review. 
The. last five hypotheges relate to the third research 
~~ objective which is to evaluate the stocking of cephalo-
sporins in hospitals. 
There is a significant difference in the stocking status 
a m.o :n g the t h r e ~~ gene r at i on s o f c e ? h a 1 o s p or i n s • 
There is a significant difference in the stocking statu~ 
of the three generations of cephalosporins. 
Hypothesis 16 
The t o t a 1 n 11mb e r o f c e p h a 1 o s p o r in s s to c k e d i s d e p ,c~ n d en t 
upon the implementation dat~ of DRG's • 
.!:!..Y..Q.Q_ t h e s i s 1 7 
The total number of c~phalosporins stocked is dependent 
U?On the te1ching status of the hospital. 
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Hypothesis 18 
The total number of cephalosporins stocked is depend2nt 
upon the bedsize of the hospital. 
METHODOLOGY 
This stu~.y utilizes data collected from hospital~in all 
ni.ne census regions of, L-.he United States. A questionnaire 
( s e e A p p en d i x 1 ) \va s sen t to 1 0 0 !-. o s p i t a 1 s i n Jan u a r y of 
1985~ The response rate was 86%. One hospital was dropped 
from the study because its formrrlary system was in the 
process of being developed. Table 1 describes the SMmple 
of the study. 
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TABLE l 
DESCRIPTION OF THE SAMPLE 
!-----------------!----------------!----------------! 
! TEACHlNG ! DRG HOSPITAL 
HOSPITAL ! IMPLEMENTATION ! BEDSIZE 
STATUS 
!-----------------!----------------!----------------! 
! 55 teaching ! 53 hospitals 44 hospitals 
hospitals with DRGs (250 beds 
Z8 non tea c i1i n g i-T2-h o :-; p iLal_s_i_2_3_h _,spi-t a 1-s--i 
hospitals ! with no DRG! 250-500 beds ! 
2 undetermined! 
! 
13 hospitals 
>500 beds 
!-----------------!----------------!----------------! 
!---------------------------------------------------! 
! GEOGRAPHI.CAL DISTRIBUTION OF THE SAMPLE ! 
! - -·-··--- ---------- ·- -·-- ---·------------------------·---- -·- ! 
! 7 hospitals in ! 2 hospitals in ! 14 hospitals in! 
New England Mideast South A~laniic ! 
10 ho'-;pi tals. in 
G:~eat Lakes 
2 hospitals in 
Mid south 
14 hospitals in! 
Plain ! 
!' 7 hospitals in 13 hospitals in! 14 hospitals in! 
! Southwest ! Rocky Mountain ! Farwest ! 
!-----------------!----------------!----------------! 
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Cephalosporins Studied 
Thirteen cephalosporins were incorporated in the study. 
Of the cephalosporins, fourteen brand name products were 
considered: 
!----------------!---------------!-----------------! 
GENERATION ! CHEMICAL NAME ! BRAND NAME 
!----------------.---- ·----------!~~~~~~~~==~~---------------
1 
1 
1 
CEFAZOLIN 
CEPHALOTHIN 
CEPHAPIRIN 
ANCEF, KEFi~OL 
KEFLIN 
CEFilDYL 
!----------------!---------------!-----------------! 
! 2 GEFAMANDOLE MANDnL. ! 
2 CEFOXITIN MEFOXIN 
2 CEFONICID MONOCID 
2 CEFORANID PRECEF 
2 CEFUROXIME ZINACEF 
3 CEFOTAXIME CLAFORAN 
3 MOXALACTAM MOXAM 
3 CEFOPERAZONE CEFOBID 
3 CEFTIZOXIME CEFIZOX 
3 CEFTRIAXONE ROCEPHIN 
!----------------!---------------! -·------~--------! 
Statistical Tests 
Hypotheses (with the exception of hypothesis 6) were 
tested by usirtg chi-square statistical test.::; (at alpha 
level of 0.05). When the overall chi-square was found to 
be significant, follow-up procedures were performed (57). 
In these cases, generations of cephalosporins were 
compared. Hypothesis 6 was tested by us~ng Speacman's r~nk 
order correlation te·;t in order to determine whether there 
was a relationship between formulary rejection and year of 
marketing. 
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FINDINGS 
The find"i.Hgs relative to ea{:h hypothesis are presented in 
this chapter. 
HYPOTHESES 1 THROUGH 5: 
These 
approval status of cephalosporins. 
Testing ~othesis l 
Hypothesis 1 was designed to study the formulary approval 
stat::s of cephalosporins . To test this hypothesis, full 
approval and restricted approval status were combined to 
indicate that a drug was on formulary. Formal rejection, 
planned review and no plans to review were combined to 
indicate that a drug was not on formulary. The results of 
this analysis are summarized i~ Table 2. 
TABLE 2 
FORMULARY STATUS OF CEPHALOSPORINS 
BY GENERATION 
!------------------!---------!---------!---------! 
! 1ST GEN.! 2ND GEN.! 3RD GEN.! 
!------------------!---------!---------!---------! 
ON FORMULARY l 137 192 177 l 
!------------------!---------!---------!---------! 
! NOT ON FORMULARY l 119 ! 233 ! 248 ! 
!------------------!---------!---------! --- ·-----! 
! TOTAL ! /~56 1 .. 25 ! 425 
!------------------!---------!---------!---- ·----! 
df=2 Chi-sqaare=9.16 alpha=0.05 p<0.02 
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Table 2 demonstrates that there are significant 
differ~~nces in the rate of formulary approval am~1ng the 
three generations of cephalosporins. Follow-up tests were 
conducted to determine which generations were the cause of 
the significance. 
there is a significant difference between first and third 
generation cephalosporins in the nil: e of formulary 
approval (respectively 53% and 41.6%). On the other hand, 
the second and third generatio~ cephalosporins rate of 
approval as well as the first ~nd second generation 
cephaJ.osporins 
significantly. 
rate of approval do 
When the rate of formulary approval was 
looking at each drug independently,among 
differ 
examined by 
all three 
g e r, e r a t i on s , four drugs were responsible for more than 
half of the total number of cephalosporins that received 
formulary approval. These products are CPfazolin (86), 
cefoxitin (82), cefotaxime (57) and cefoperazone (53). 
Table 3 indicates the number of instancP.s as well as the 
rate of formulary approval for each drug in 
hospital sample. 
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TABLE 3 
FORMULARY APPROVAL OF CEPHALOSPORINS 
!------------!------------------!---------- ·-------! 
!DRUG !FORMULARY APPROVAL! NOT ON FORMULARY ! 
! # % ! # % 
!------------!------------------!------------------! 
!CEFAZOLIN* ! 86 (100%) 0 (100%) 
!CEPHALOTHIN ! 31 (36.5%) 54 (63.5%) 
!CEPHAPIRIN ! 20 (23.5%) ! 65 (76.5%) ! 
!------------!------------------!------------------! 
;-------------.--! "'CETAHANlJULT! 4--s-c-s-o--:-s-%-)-i 3/_(_4-3--;-~%-)--!'------
!CEFOXITIN 82 (96.5%) ! 3 (3.5%) ! 
!CEFONICID 27 (31.7%) ! 58(69.4%) 
!CEFORANIDE 10 (11.7%) 75 (88.2%) 
!CEFUROXIME 25 (2q.5%) ! 60 (70.5%) ! 
!------------!------------------!-------------------! 
!CEFOTAXIME 57 (67%) ! 28 (32.9%) 
!MOXALACTAM 26 (30.6%) 59 (69.4%) 
!CEFOPERAZONE! 53 (62.3%) 32 (37.6%) 
!CEFTIZOXIME ! 34 (40%) 51 (60%) 
!CEFTRIAXONE ! 7 (8%) ! 78 (92%) 
!------------!-------------------!------------------! 
!TOTAL ! 506 ! 600 
!------------!------------------!--------- ·--------! 
* In one case, cefaz!,lin was on formulary under Ancef and 
Kefzol. Ancef was full approval status and Kefzol was 
restricted approval sta':us. 
Testing £f Hypothesis l 
Formulary approval status was further divided into fu·l.l 
approval and restricted approval. The results are 
summarized in Table 4. 
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TABLE 4 
APPROVAL STATUS BY GENERATION 
!-------------------!------~---!----------!---------! 
!FORMULARY APPROVAL ! 1ST.GEN. ! 2ND.GEN. ! 3RD.GEN.! 
!------------- ·-----!------~---!----------!- --------! 
!FULL APPROVAL 124 163 125 
!-------------------!--------. !----------!-------- ·! 
!RESTRICTED APPROVAL! 13 29 ! 52 ! 
!-------------------!------~---!----------!---------! 
TOTAL ! 137 ! 192 177 
!-------------------!----------!-- --
df=2 X2=22.66 alpha=O.OS p<O.O)l 
These figures show that there is a significant difference 
in the rate of full approval versus restricted approval 
among the three generations of cP.phalosporins. Follow-up 
proce~Jres were conducted to determine which generations 
contributed to the significant difference. The results of 
the post hoc procedures indicate a significant differ8nce 
due to the rate of restricted approval of third generation 
cephalosporins. Third generati:1n cephalosporins were shown 
to have a superior number of restricted formulary status 
(p<0.001). This is expected because third generation 
cephalosporins have a high potential to induce bacterial 
resistance and are generally !nor~ expensi~e than their 
first and second generation counterparts. Therefore, 
third generation cephalosporins are considered to be 
second-line agents in antibiotic therapy. Restricted 
formulary status oftentimes is implemented to l~mit their 
usage. First and second ~eneration cephalosporins do not 
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differ significsrrtly with regards to their rate of 
restricted formulary status. 
When th~ restricted formulary status is studied i'or 
individnal cephalosporins, the rate of full approval 
formulary status rate is greater than restricted formulary 
s a u s w 1 t n-----Th e ex c e p t 1 on o f c e for an i-d"e.---,---,c. e-fyr:ta1c~n1~------a11-d------­
moxalacta:n. 
All cephalosporins have a percentage of restricted 
approval less than 20% of the overall approval rate. Third 
g',er,era t ion ce pha:'.o spor ins have the highest percentage of 
restricted approval status. Ceftriaxone is the exception 
among third genHration cephalosporins. Its full approval 
st~tus is only 2.35%. This can be explained by the recent 
marketing of this product at the time of the study 
(January- March, 1985). 
First and second generation cephalosporins are rarely 
restricted with a percentage of restricted approval status 
constantly below 10%. These results are summarized in 
Table 5. 
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TABLE 5 
FULL APPROVAL STATUS VS. RESTRICTED APPROVAL STATUS 
OF CEPHALOSPORINS 
!------------!----------------!------------!----~------! 
! ! FULL ~PPROVAL ! RESTRICTED ! RATIO ! 
APPROVAL ! FA*/RA* 
!------------!----------------!------------!-----------! 
!CEFAZOLIN 85 (100%) 1 (1%) ! 99%/1% ! 
!CEPHALOTHIN 23 (27%) 8 (9.5%) !74.2%/25.8%! 
!CEPHAPIRIN 16 (18.8%) 4 (4.7%) !80%/20% 
if------
!CEFAMANDOLE 44 (51.7%) 4 (4.7%) 91.6%/8.3%! 
!CEFOXITIN 76 (89.4%) 6 (7%) 92.6%/7.4%! 
!CEFONICID 20 (23.5%) 7 (8.2%) 74%/26% 
!CEFORANIDE 5 (5.8%) 5 (5.8%) 50%/50% 
!CEFUROXIME 18 (21%) ! 7 (8.2%) 72%/28% 
! ------------! --------------- -! ---- ·-------! --- ·- . -----! 
!CEFOTAXIME ! 43 {50.6%) ! 14 (16.5%)!75.4%/24.6%! 
!MOXALACTAM ! 16 (18.8%) ! 10 (11..7) !61..5%/38.5%! 
!CEFOPERAZONE! 41 (48,2%) ! 12 (14.1%):77.4%/22.6%! 
!CEFTIZOXIME ! 23 (27%) ! 11 (13%) !67.6%/32.4%! 
!CEFTRIAXONE ! 2 (2.3%) ! 5 (5.8%) !28.6%/71.4%! 
!-------------!----------------!------------!-----------! 
TOTAL 412 94 ! 
. !------------!----------------!------------!-----------! 
FA= FULL APPROVAL 
RA= RESTRICTED APPROVAL 
FA*= NUMBER OF FA / TOTAL NUMBER OF FORMULARY APPROVAL FOR 
EACH DRUG 
RA*= NUMBER OF RA/TOTAL NUMBER OF FORMULARY APPROVAL FOR 
EACH DRUG 
Testing Hypothesis 3 
First generation cephalosporins were no~ considered in 
testing Hypothesis 3 because of their low incidence of 
restricted approval on [·.he hospital fo::-mularies. 
Consequently, it was not possible to include that 
generation of cephalosporins in the chi.-square statistical 
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test. The reasons why second and third gen~ration 
c~phalo~porins were for~ulary restricted are analy~ed in 
Table 6. 
TABLE 6 
REASONS FOR 2ND GENERATION AND 3RD GENERATION 
CEPHALOSPORINS RESTRICTED APPROVAL STATUS 
!--------------------!------------!------------~ 
!2ND GEN.R.A.!3RD GEN.R.A.! 
!----------------~---!------------!------------! 
!SPECI~IC DIAGNOSIS ! 10 ! 16 ! 
!------------------ ·-!------------!------------! 
!ID. CONSULTATION ! 8 24 ! 
!--------------------!------------!-- ·---------! 
! OTHERS>:< ! 9 ! 8 ! 
!--------------------!------------!------------! 
df=2 X2=3.87 alpha = 0.05 N.S. 
OTHERS·: special re;uest, pharmacy interve:1~ion, trial use, 
P&T Committee intervention. 
Secon& and third generation C~?halosporins did not show 
any significant difference regarding reasons for their 
formulary restriction. Sp~cific d i ·"l g n o s i s and ID 
consultation are the most frequently selected reasons for 
the restriction of these two generations of 
cephalosporin~;. 
A nu~ber of second an~ third geheration cephalosporins 
(ceftizoxirne and ceftriaxone) were listed as restricted 
approval due to trial use. Among those o~ trial use, 
ceforanide and cefonicid were currently being investigated 
for surgical prophylaxis and cefuroxirne waE: on 
36 
trial for infant meningi.tis. With respect to those 
cephalo~porins listed under restricted approval, specific 
dLagnosis was recorded cefoxitin, cefonicid, 
cefam:~ndole 1 cefuroxime. Surgical prophylaxis, puh10nary 
and pediatric infections were the major indic1tions for 
these second genera ti ,)n cephalo -;porins. 
A~l third generation cephalosporins were restricted with 
regard to formulary acceptAnce. This emphasi~es that 
these 11roducts are normally considered to be secon::'.-line 
agents. The restricted formulary status was indicated when 
aminoglycoside therapy was not adequate or when 
microorganisms were only sensitive to these products (e.g. 
Pseudomonas infections, bacterial meningitis, and 
cholecystitis). In one case, moxalactam was l·estricted 
because of its potential bleeding problems. Formulary 
restriction appeared to be used to draw the physician's 
attention to the possible side effects of the druu. 
Testing Hypotheses ~ 5 and 6 
HypotheGes 4, 5 &n~ 6 are con~erned with th~ relationship 
between the number of cephalosporins accepted on formulary 
and specific parameters. These parameters include the 
implementation of DRGs, 
hospital bedsize. 
hospital te~ching status, 
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and 
First, th~ different combinations among each ga~eration 
of cephalosporins admitted on formulary were studied 
as well as the number of cephalosporins admitted on 
formulary. The results are indicated in Tables 7 through 10. 
TABLE 7 
NUMBER OF CEPHALOSPORINS ADMITTED ON FORMULARY 
!-------------~----!------------ ·!------------! 
! NUMBER OF ! 
! CEPHALOSPORINS ! RESPONDENTS ! PE~CENTAGE ! 
! ON FORMULA'H ! ! 
! ---------------..,.--! --- ·---------! ------------! 
2 3 3.5% 
1------- -----------!-------------!------------! 
3 ! 5 .'5.9% ! 
!------------------!---- ·----- ·--!------------! 
! 4 20 ! 23.5% ! 
! ------ ·-----------! -------- . ·---! ------- ··----! 
! 5 ! 17 ! :LO ! 
!------------------!-------------!------------! 
! 6 ! 13 ! 15.3% 
!------------------!-------. ----!------------! 
7 ! 9 ! 10.6% ! 
!------------------!-------------!------------! 
8 7 ! 8. ?% 
!--------------- ·--!-------------!----- ·------! 
9 7 ! 8. 2% 
!------------------!- ·-----------!------------! 
10 3 
!--~---------------!-------- ·----!------------! 
! :i.2 ! 1 ! 1. J.% ! 
!--- ·--------------!-------------!------------! 
! TOTAL ! 85 !100.0% 
!------------------!------- ·-----!------------! 
As ~., e en by the s e d 9. t a , the m o s t f r e que n t numb e r o f 
cephalosporins admitted on formulary was tour (23.5% of 
the hospitals in the sample). Hospitals with four, five, 
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and six cephalosporins admitted to their formulary 
represent 58.R% of the total. When considering only first 
gHneration ~ephalosporins, one is the most freqJent number 
admitted to formularies (58.8% o! all respondents). In 
this case, cefazolin was always the sole first generation 
cephalosporin~ ~ere selected, cefazolin and cephalothin 
was the most frequently chosen combination. Only seven 
hospitals had all three first generation cephalosporins on 
their formulary. This appears tJ confirm the trend to 
eliminatB therapeutic duplicaticn from the formulary. 
These results are summarized in Table 8. 
T.~BLE 8 
COMBINATI8NS OF FIRST GENERATION CEP.nALOSPORINS 
ADMITTED 0~ FORMULARY 
!----------------!--------------!------------!------------! 
! NUMBER COMBINATIONS ! RESPCNDENTS! % OF T07AL 
! OF 1 ~ T GEN. # % 
! ON FOHMULARY 
!---------------!--------------!------------!-------------! 
ONE ! CEFAZOLIN 50 100% ! 58.7% ! 
!;;;=;;=;;;;;;==!;=;;;===;==;=;!;=======;=;=!=;;;;=;;;===! 
! CEFAZOLIN + ! 21 75% 24.7% ! 
! CEPHALOTHIN ! ! 
TWO !--------------!------------!------------! 
! CEFAZOLIN + 7 25% 8.3% 
! CEPHAPIRIN 
!;;=;;=;;==;;==;!==============!========;=;=!===;;=======! 
! THREE CEFAZOLIN + 7 100% ! 8. 3% 
! CEPHALOTHIN +! 
! CEPHAPIRIN + ! 
!---------------!--------------!------------!------------! 
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Two second generation cephalosporins is the most 
frequently selected number in terms of formulary 
acceptance. The top three (out of five) second generation 
cephalosporins represent 86% of all second generation 
cephalosporins admitted to the formularies of our sample. 
Three hospitals had no second generation cephalosporins 
admitted on their formulary while two hospitals had all 
five products admitted on their formulary. Cefoxitin was 
the most popular second generation cephalosporin in terms 
of formulary acceptance. This drug was present in every 
combination of second generation cephalosporins. 
Table g lists the top three combinations of second 
generation cephalosporins in our 85 hospital sample. 
TABLE 9 
COMBINATIONS OF SECOND GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!-------------!----------------!-------------!----------! 
NUMBER ! COMBINATIONS RESPONDENTS !% OF TOTAL! 
! OF 2ND. GEN . ! ! 
! ON FORMULARY! # % 
!-------------!----------------!-------------!----------! 
! ! CEFOXITIN + 19 54.3% 22.3% ! 
TWO CEFAMANDOLE 
!----------------!-------------!----------! 
CEFOXITIN + 9 25.7% ! 10.5% ! 
CEFUROXIME 
!----------------!------~------!----------! 
CEFOXITIN + 7 22% ! 8.2% ! 
CEFONICID 
!=============!================!=============!==========! 
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TABLE 9 (CONT.) 
COMBINATIONS OF SECOND GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
THREE 
CEFOXITIN + 
CEFAMANDOLE + 
CEFONICID 
8 40% 9.4% 
1----------------1-------------l----------1 
CEFOXITIN + I 8 40% I 9.4% 
CEFAMANDOLE +I 
I GEFURUXTfft; --------------------
1----------------l-------------l----------l 
I CEFOXITIN + I 3 15% I 3.5% I 
CEFAMANDOLE + I 
CEFORANID 
1----------------1-------------l----------1 
CEFOXITIN + I 1 5% I 1.1% I 
CEFONICID + 
CEFORANID 
1=============1================1=============1==========1 
! ONE I CEFOXITIN I 17 100% I 20% I 
l-------~-----l----------------l-------------l----------1 
Eigh.t.y 'Percent of the hospitals in our sample had ·either 
one, two or three third generation cephalosporins admitted 
onto their formularies. Two is the most frequent number of 
third generation of cephalosporins admitted on formulary 
(31.8% of all respondents). Six hospitals had admitted no 
third generation cephalosporins to their formularies. No 
hospitals admitted all five third generation 
cephalosporins to their formulary. 
When compared with the other generations, third generation 
cephalosporins have more combinations of products selected 
for formulary approval. This may reflect the fact that 
there are more specific indications listed for this 
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gene·cation of cephalosporins. Cefotaxime was the most 
frequently selected third generation cephalosporin for 
formulary acceptance. However, this product among third 
generation cephalosporins was less predominant than 
cefazolin and cefoxitin in their respective generations. 
Table 10 summarizes the different possible combinations 
for the top three choices of third generation 
cephalosporins admitted on formulary. 
TABLE 10 
;£DMBINATIONS OF THIRD GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!--------~----!--------------!-------------!------------! 
! NU1'1BER . ·· ! COMBINATIONS ! RESPONDENTS ! % OF- TOTAL 
! OF 3RD GEN # % 
!ON FORMULARY! 
!-------------!--------------!-------------!------------! 
! !CEFOTAXIME + ! 12 44.4%! 14.1% ! 
!CEFOPERAZONE 
!--------------!-------------!------------! 
!CEFOPERAZONE +! 6 22.2%! 7.05% ! 
!CEFTIZOXIME 
!--------------!-------------!------------! 
!CEFOTAXIME + ! 4 14.8%! 4.7% ! 
!CEFTIZOXIME 
TWO !--------------!-------------!------------! 
!CEFOTAXIME + ! 4 14.8%! 4. 7% ! 
!MOXALACTAM 
!--------------!-------------!------------! 
! CEFOPERAZONE+ ! 1 3. 7% ! 1. 1% ! 
!MOXALACTAM 
!=============!==============!=============!============! 
!CEFOTAXIME ! 11 44% ! 12.9% ! 
!--------------!-------------!------------! 
! CEFOPERAZONE 7 28% ! 8. 2% 
ONE !--------------!-------------!------------! 
! CEFTIZOXIME ! 6 24% ! 7. 05% 
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TABLE 10 (CONT.) 
COMBINATIONS OF THIRD GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
.!--------------!-------------!------------! 
!MOXALACTAM ! 1 4% ! 1.1% 
" '============='=============='============='============' i icEFOTAXIME + i 8 47% i 9.4% i 
! !MOXALACTAM + ! ! ! 
! ! CEFOPERAZONE ! ! ! 
i ! l !---- ------- !:-------
!CEFOTAXIME +! 4 23.5%! 4.7% 
!CEFOPERAZONE +! 
!CEFTIZOXIME 
!--------------!-------------!------------! 
!CEFOTAXIME + i 2 11.7%! 2.3% 
THREE !CEFOPERAZONE +! 
!CE~TRIAXONE ! 
!--------------!-------------!------------! 
!MOXALACTAM + ! 2 11.7%! 2.3% 
!CEFOPERAZONE +! 
!CEFTIZOXIME 
!--------------!-------------!------------! 
!CEFOTAXIME + 1 5.8%! 1.1% ! 
! MOXALACT AM + ! ! 
! CEFTIZOXH1E ! 
!-------------!--------------!-------------!------------! 
Chi-square tests were conducted to analyze hypotheses 4, 5 
and 6. These hypotheses examine the influence of DRG 
implementation, hospital teaching status and hospital 
bedsize on the number of cephalosporins admitted on 
formulary . The results are indicated in Tables 11 through 
21. 
It was not possible to test the influence of DRGs on the 
total number of cephalosporins admitted on formulary 
because of the low response rate ( 2 cells with expected 
43 
values less than 5 ). 
TABLE 11 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF FIRST GENERATION 
CEPHALOSPORINS ADMITTED ON FORMULARY 
!-------~-------!--------!----------! 
NUMBER ! DRGS ! NO DRGS ! 
OF 1ST GEN. 
ON FORMULARY 
!~---~~-~----------!---------
ONE ! 31 19 
!---------------!--------!----------! 
! TWO 20 ! 8 
!---------------!--------!----------! 
THREE 4 3 
!---------------!--------!----------! 
df;2 X2;0,89 alpha;O,OS N.S. 
The figures in Table 11 demonstrate that there are no 
significant differences in the number of first generation 
cephalosporins admitted on formulary in regard to DRG 
implementation. 
TABLE 12 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF 2ND GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!----------!----------! 
NUMBER DRGS ! NO DRGS 
! OF 2ND GEN. 
! ON FORMULARY 
!---------------!----------!----------! 
TWO ! 23 ! 12 ! 
!---------------!----------!----------! 
! THREE 13 ! 8 
!---------------!----------!----------! 
ONE 11 6 
!---------------!----------!----------! 
df=2 X2=0.08 alpha=O.OS N.S. 
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The figures in Table 12 demonstrate that there are no 
significant differences in the number of second generation 
cephalosporins admitted on formulary in regard to DRG 
implementation. 
TABLE 13 
!---~--------------"~':-N-F-0-t:J-E-N-&E-8-F-B-H-G-I-M-P-b-EM-E-N-'I'-A-T~I-O-N-----------~ 
ON THE NUMBER OF THIRD GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!----------!----------! 
NUMBER DRGS NO DRGS ! 
! OF 3RD GEN. 
! ON FORMULARY ! 
!---------------!----------!----------! 
TWO 22 5 
!---------------!----------!----------! 
! ONE 14 ! 11 
!---------------!----------!----------! 
! THREE ! 8 ! 8 
! -·--------------! ----------! -- ·-------! 
df=2 X2=5.67 alpha=0.05 N.S. 
The figures in table 13 demonstrate that there are no 
significant differences Ln the number of third generation 
cephalosporins admitted on formulary and DRGs 
implementation. 
DRG implementation has no influence on the number of 
cephalosporins admitted on formulary when cephalosporins 
are considered by generations. However, at an alpha level 
of 0.1, the number of third generation cephalosporins 
admitted on formulary is significantly less in those 
hospitals in which DRG's are implemented. In this case, 
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the implementation of DRG appears to prioritize the focus 
on the formulary acceptance of third generation 
cephalosporins which is an area of high expenses. 
TABLE 14 
INFLUENCE OF HOSPITAL TEACHING STATUS 
I'nJMWE_R_O_F_C_E_r-:tt7\-t-G~J3l)-R-r-N-s-kSN-I-T-T-E-B-8N-F-8-H-M-B-b-A-R-Y:--------
!-------------------!----------!----------!-------! 
NUMBER TEACHING NON ! TOTAL ! 
! OF CEPHALOSPORINS ! TEACHING! 
! ON FORMULARY 
!-------------------!----------!----------!-------! 
! FOUR ! 10 ! 10 ! 20 ! 
!-------------------!----------!----------!-------! 
FIVE 1 16 17 
r--------------------! ----------! ----------! -------! 
SIX ! 3 ! 10 ! 13 ! 
!--------------------!----------!----------!-------! 
df:2 X2=9.08 2 cells<S.O alpha=O.OS p<0.02 
df:1 X2=8.56 alpha=O.OS p<O.Ol 
It was not possible to perform a chi-square test on the 
first three choices of cephalosporins admitted on 
formulary. This is due to the number of cells being less 
than 5.0. However, when the test is performed on the 
first two rows, the figures in table 14 demonstrate a 
significant difference in the number of cephalosporins 
admitted on formulary according to the hospital teaching 
status. There are less cephalosporins admitted onto 
formulary in teaching hospitals. This may be the result of 
most teaching hospitals having an infectious disease 
service. This department normally assists the P&T 
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committee in, among other things, preventing therapeutic 
duplications. 
TABLE 15 
INFLUENCE OF HOSPITAL TEACHING STATUS 
ON THE NUMBER OF FIRST GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
NUMBER 
OF 1ST GEN. 
ON FORMULARY 
TEACHING NON TEACHING 
!---------------!-----------!--------------! 
! ONE ! 15 ! 35 ! 
!---------------!-----------!--------------! 
! TWO ! 8 ! 20 ! 
!---------------!-----------!--------------! 
THREE 2 3 
!---------------!-----------!--------------! 
df=2 X2=0.26 alpha=0.05 N.S. 
The figures in Table 15 demonstrate that there are no 
significant differences in the number of first generation 
cephalosporins admitted on formulary due to the hospital's 
teaching status. 
TABLE 16 
INFLUENCE OF HOSPITAL TEACHING STATUS 
ON THE NUMBER OF 2ND GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!-----------!--------------! 
! NUMBER ! TEACHING ! NON TEACHING 
! OF 2ND GEN. 
! ON FORMULARY 
!---------------!-----------!--------------! 
! TWO 10 24 
!---------------!-----------!--------------! 
! THREE ! 6 14 ! 
!---------------!-----------!--------------! 
! ONE ! 7 ! 10 ! 
!---------------!-----------!--------------! 
df=2 X2=0.79 alpha=0.05 N.S. 
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The figures in Table 16 demonstrate that there are no 
significant differences in the number of second generation 
cephalosporins admitted on formulary due to the hospital's 
teaching status. 
1 ·~GE--1~'-------------------------------------
INFLUENCE OF HOSPITAL TEACHING STATUS 
ON THE NUMBER OF THIRD GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!-----------!--------------! 
NUMBER ! TEACHING ! NON TEACHING ! 
! OF 3RD GEN. 
! ON FORMULARY ! 
!---------------!-----------!--------------! 
TWO ! 6 ! 21 ! 
!---------------!--~--------!--------------! 
! ONE ! 6 19 
!---------------!-----------!--------------! 
THREE ! 7 ! 7 ! 
!---------------!-----------!--------------! 
df=2 X2=3.92 alpha=O.OS N.S. 
The figures in Table 17 demonstrate that there are no 
significant differences in the number of third generation 
cephalosporins admitted on formulary due to the hospital's 
teaching status. 
Hospital teaching status has a significant influence on 
the overall number of cephalosporins admitted on 
formulary. Non-teaching hospitals tend to admit a larger 
number of cephalosporins on their formulary (p<0.02). This 
phenomenon might be related to the absence of an 
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infectious disease specialist or a clinical pharmacist on 
the medical staff assisting the P&T Committee. On the 
other hand, when the total number of cephalosporins is 
broken down by generation, the hospital teaching status 
was not found to have any influence. 
and >250 beds. Medium and large hospitals were considered 
together in order to be able to perform the chi-square 
test. The results of these analyses are presented in 
Tables 18 through 21. 
TABLE 18 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF CEPHALOSPORINS ACCEPTED ON FORMULARY 
!--------------------!----------!----------!---------! 
!NUMBER ! SMALL MEDIUM +! TOTAL ! 
!OF CEPHALOSPORINS <250 LARGE 
!ON FORMULARY >250 
!---------------------!----------!----------!---------! 
FOUR 8 ! 11 19 ! 
!--------------------!----------!----------!---------! 
! FIVE ! 13 ! 4 ! 17 ! 
!--------------------!----------!----------!---------! 
! SIX ! 7 6 13 ! 
!--------------------!----------!----------!---------! 
df=2 X2=4.41 alpha=0.05 N.S. 
The figures in Table 18 demonstrate that there are no 
significant differences in the total number of 
cephalosporins admitted on formulary due to the hospital's 
bedsize. 
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TABLE 19 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF 1ST GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!---------!----------! 
!NUMBER SMALL MEDIUM+ ! 
!OF 1ST GEN. <250 LARGE 
!ON FORMULARY >250 
~~~=-~'!~======~'------------------
ONE 25 29 
!---------------!---------!----------! 
! TWO . 1 7 ! 11 ! 
!---------------!---------!----------! 
THREE 2 4 
!---------------!---------!----------! 
df;2 X2;1,68 alpha;Q,OS N.S. 
· The figures in Table 19 demonstrate that there are no 
• significant differences in the number of first generation 
~ cephalosporins admitted on formulary due to the hospital's 
bedsize. 
TABLE 20 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF SECOND GENERATION 
ADMITTED ON FORMULARY 
!---------------!---------!----------! 
!NUMBER ! SMALL MEDIUM+ ! 
!OF 2ND GEN. <250 LARGE 
!ON FORMULARY >250 
!---------------!---------!----------! 
T\W ! 21 ! 14 
!---------------!---------!----------! 
THREE ! 12 ! 8 ! 
!---------------!---------!----------! 
ONE 6 ! 10 ! 
!---------------!---------!----------! 
df;2 X2;2,53 alpha;Q,OS N.S. 
so 
The figures in Table 20 demonstrate that there are no 
significant differences in the number of second generation 
cephalosporins admitted on formulary due to the hospital's 
bed size. 
TABLE 21 
lr'iFGUE-l'fCE_O_F_H-o-s-p-r-TP.L-;1-E-n-s-r--z-'r..F:---------------
ON MUBER OF THIRD GENERATION CEPHALOSPORINS 
ADMITTED ON FORMULARY 
!---------------!---------!----------! 
!NUMBER ! SMALL MEDIUM ! 
!OF 3RD GEN. <250 LARGE 
!ON FORMULARY >250 
!---------------!---------!----------! 
! TWO ! 14 12 ! 
!---------------!---------!----------! 
ONE ! 17 ! 8 
!---------------!---------!----------! 
! THR_E 7 ! 8 ! 
!---------------!---------!----------! 
df=2 X2=1.99 alpha=O.OS N.S. 
The figures in Table 21 demonstrate that there are no 
significant differences in the number of third generation 
cephalosporins admitted. on formulary due to the hospital's 
bedsize. 
Hospital bedsize was shown to have no influence on the 
total number of cephalosporins admitted on formulary when 
cephalosporins are considered overall or divided into 
generations. The type of medical and surgical services 
available in the hospital may influence the selection of 
cephalosporins more than hospital bedsize. Although data 
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on the number and type of services were not available in 
this study, future research may include these independent 
variables as a possible influence on the number of 
cephalosporins admitted on hospital formularies. 
'P-e-sti--nz-:H-y-p-o-t-h-e-s-e-s-----i_-'I'-h-r-o-u-g-h-l-3--------------------
Hypothesis 7 is concerned with the possible relationship 
of the marketing year of the drug and the formulary 
status. The results are presented in Table 22. 
TABLE 22 
RELATIONSHIP 
BETWEEN FORMULARY STATUS OF CEPHALOSPORINS 
AND YEAR OF MARKETING 
!----------------!------------!-----------!------! 
! CEPHALOSPORINS ! FORMULARY ! MARKETING ! RANK ! 
! REJECTION ! YEAR 
!----------------!------------!-----------!------! 
CEFTRIAXONE 78 (93%)! 1984 ! 13 ! 
!-----·-----------!------------!-----------!------! 
! CEFORANIDE ! 75 (89.4%)! 1984 ! 12 ! 
!----------------!------------!-----------!------! 
! CEPHAPIRIN ! 65 (77.6%)! 1974 ! 3 ! 
! ------ ·---- ·----!-- ·--- . ·---! -----------! ------! 
! CEFUROXIME ! 60 (71.7%)! 1983 ! 10 ! 
!-------------- -!----·-------!-----------!------! 
! MOXALACTAM 59 (70.6%)! 1981 7 ! 
!----------------!------------!-----------!------! 
! CEFONICID ! 58 (69.4%)! 1984 ! 11 
!----------------!------------!-----------!------! 
! CEPHALOTHIN ! 54 (64.7%)! 1964 ! 1 ! 
!----------------!------------!-----------!------! 
! CEFTIZOXIME ! 51 (61.2%)! 1983 ! 9 ! 
!----------------!-------------!-----------!------! 
! CEFAMANDOLE ! 37 (44.7%)! 1978 ! 4 ! 
!----------------!------ ·-----!-----------!------! 
! CEFOPERAZONE 32 (38.8%)! 1982 8 
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TABLE 22 (CONT.) 
RELATIONSHIP 
BETWEEN FORMULARY STATUS OF CEPHALOSPORINS 
AND YEAR OF MARKETING 
!----------------!------------!-----------!------! 
! CEFOTAXIME ! 26 (31.8%)! 1981 ! 6 ! 
!----------------!------------!-----------!------! 
! CEFOXITIN ! 3 (4. 7%)! 1979 ! 5 ! 
!----------------!------------!-----------!------! 
CEFAZOLIN 0 (0%) ! 1974 ! 2 ! 
Spearman coefficient = -.56 p<0.05 alpha=0.05 
The relationship between the year that the drug was 
marketed and the formulary status was tested using a 
Spearman rank correlation test. The correlation 
coefficient was -0.56, indicating a moderately negative 
correlation between the marketing year and the formulary 
status. The newer cephalosporins are more likely to be 
rejected from the formulary by the P&T Committee. 
This may due to the lack of originality in the 
spectrum of activity, therapeutic indications of these new 
drugs allied with a poor cost-benefit ratio. 
Hypotheses 8 through 13 are concerned with the non-
formulary status of cephalosporins. Prior to testing, the 
non-formulary status of cephalosporins was divided into 
formulary rejection, non-formulary status with planned 
review and non-formulary status without planned review. In 
some cases, respondents checked two answers. When 
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rea1·ondents selected formulary rejection and planned 
review status, planned review status was chosen. When 
respondents selected formulary rejection and non-formulary 
status with no plans to review, no plans to review status 
was chosen. The results relating to the non-formulary 
status of cephalosporins are presented in Table 23. 
TABLE 23 
NON FORMULARY STATUS OF CEPHALOSPORINS 
BY GENERATION 
! --------- ·----- -----! ----------! ---------! ---------! 
t ! 1 S T •:; EN • ! 2ND G EN • ! 3 R D G EN . ! 
!--------------------!----------!---------!---------! 
! FORMULARY REJECTION ! 79 110 104 ! 
! ---- ·---·-------- ·----! ----------! ---------! ---------! 
! NON-FORMULARY WITH ! 2 ! 40 ! 63 
!PLANS T~ REVIEW 
!-------·-------------!----------!---------!---------! 
!NON FORMULARY WITH ! 38 ! 79 80 
!NO PLANS TO REVIEW ! 
!--------------------!----------!---------!---------! 
df=4 X2=35.8 alpha=O.OS p<0.001 
The figures in Table 23 demonstrate that there is a 
significant difference in the formulary rejection status 
among the three generations of cephalosporins. Follow-up 
procedures were conducted to determine which generation 
was responsible for these differences. 
From the first hypothesis, third generation cephalosporins 
were found to have the greatest frequency of formulary 
rejection(247). First and second generation of 
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cephalosporins had a total of 119 and 233 formulary 
rejections respectively. First generation cephalosporins 
differ significantly from the other two generations. 
Of those first generation cephalosporins that are not on 
formulary, most of them are formally rejected. Planned 
review status was rarely selected in the first generation 
when compared to the other generations and is responsible 
for the signific~nt difference when thB chi-square test 
was performed. This.low rate might be explained by the 
length of time that first generation cephalosporins have 
been in use. Cephalothin and cephapirin are the two first 
generation cephalosporins . that are responsible for the 
non-formulary status of the first generation 
cephalosporins. 
Similar to the the first generation, formulary rejection 
was found to be the most frequent formulary status for the 
second generation of cephalosporins (p<O.OOl) with the 
exception of cefoxitin. This was expected because 
cefoxitin was found to be the one of the most widely 
accepted of all cephalosporins. 
Unlike the other generations of cephalosporins, third 
generation cephalosporins are usually rejected from the 
formulary. However, in the case of the third generation, 
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planned formulary review is more frequently selected. 
Ceftriaxone and ceftizoxime, both newly marketed drugs, 
were mainly responsible for the planned review status. The 
large number of newly marketed products in this generation 
as well as their relatively high cost may be responsible 
for the hi g Iever01 p 1 anne d review s catu-s-o-f-th-e-t-h-i-r-d.-------
generation cephalosporins. 
Hypothesis 9 is concerned with the reasons 
cephalosporins are rejected. 
rejecting cephalosporins were: 
1. No advantage:47.2% 
2. No advantage/high cost: 29.9% 
3. High cost :12.3%: 
4. No advantage/side-effect:S% 
5. Misuse:l.S% 
The major reasons 
why 
for 
Despite precited literature references concerning the 
frequent misuse of antibiotics, misuse is rarely selected 
as a reason for rejecting cephalosporins from hospital's 
formulary(1.5%). The reasons for cephalosporin formulary 
rejection are indicated in Table 24. 
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TABLE 24 
REASONS FOR 
CEPHALOSPORIN FORMULARY REJECTION 
! ---------------! ·--------! ---------! ---------! 
! ! 1ST GEN.! 2ND GEN.! 3RD GEN.! 
!------ ·--------!-- ·------!------- -!---------! 
! NO ADVANTAGE* ! 56 ! 65 ! 32 ! 
!---------------!---------!---------!---------! 
! NO ADVANTAGE>:< ! 39 38 20 
!AND HIGH COST ! 
! --------------- i - - !'~=-=-:::=-=cc=-=c=~'--=-==-=-==-=-==~'----------
HIGH COST >:< ! 23 4 13 
!---------------!---------!---------!---------! 
NO ADV ANT ACE+! 0 ! 3 ! 15 
! SIDE EFFECTS! 
!---------------!---------!---------!---------! 
! SIDE EFFECTS ~ 0 ! 0 11 ! 
!·------------- ·-!---------!---------!---------! 
MISUSE ! 0 3 2 ! 
!--------~---- -!---------!---------!---------! 
df=4 X2=14.79 alpha = 0.05 p<O.Ol 
* indicates which rows are tested 
The first three reasons for rejecting cephalosporins were 
tested. The overall chi-square was found statistically 
significant (p<O.Ol). Follow-up tests were conducted to 
determine which generations were the cause of the 
significance. The second generation cephalosporins were 
found to be the cause of the significant difference. For 
this generation, cost alone was rarely selected (4). 
Misuse was selected three times for cefonicid. This drug 
has a different dosing schedule from the other 
cephalosporins. 
The first generation of cephalosporins are mostly rejected 
for reasons of cost and/or the availability of therapeutic 
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equivalents. 
With the third generation cephalosporins, cost and the 
availability of therapeutic equivalents are the major 
reasons for formulary rejection. However, there is a shift 
towards side effects as the major reason for rejection of 
drugs wi1Chin this generation. Tn1s is mostly due to 
bleeding problems reported for moxalactam. 
Hypothesis 10 is concerned with the outcome of 
cephalosporins with planned review status. First 
generation cephalosporins were not included in the testing 
of hypothesis 10 for reasons of cells being less than 5. 
~~ This made it impossible to perform a chi-square test. The 
outcome of second and third generation cephalosporins when 
a planned review was indicated are analyzed in Table 25. 
TABLE 25 
OUTCOME OF 2ND AND 3RD GENERATION CEPHALOSPORINS 
WHEN PLANNED REVIEW 
!----------------!------------!-------------! ! 2ND GEN •. ! 3RD GEN. ! 
!----------------!------------!-------------! 
! APPROVAL 9 ! 12 
!----------------!------------!-------------! 
! UNCERTAIN ! 11 ! 20 ! 
!----------------!------------!-------------! 
! REJECTED ! 5 16 
!----------------!------------!-------------! 
df=2 X2=1.73 alpha= 0.05 N.S. 
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The fi.gures in Table 25 demonstrate that there is no 
significant difference in the expected outcomes of second 
and third generation cephalosporins when there is a 
planned review. In the cases of both second and third 
generation cephalosporins, 'uncertain' outcome is most 
frequently selected. This may be explained-oy tne--Grug 
review being conducted by the P&T committee which plays a 
determinant role in the addition or deletion of drugs from 
the formulary. 
Next, the expected outcomes for each drug was studied. The 
outcome of the first generation cephalosporins 
(cephalothin, cephapirin) was always rejection from the 
formulary. The hospitals in the sample seemed to adopt the 
trend of one first generation cephalosporin on 
formulary. Newly marketed agents (cefonicid, ceforanide and 
cefuroxime) are responsible for most of the planned review 
status in our sample. In the case of ceforanide, the 
expected outcome of its planned reviews was rejection in 5 
out of the 10 responses. This drug does not seem to 
stimulate the interest of health professionals despite a 
single daily dosing. 
Among the third generation cephalosporins, ceftriaxone had 
the highest rate of planned review status. Rejection was 
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rarely pr0jected (4 out of 28). Moxalactam, because of its 
side-effects, was expected to be rejected after its 
planned review in four out of five cases. This probably 
confirms the disfavor of this product among health 
professionnals. 
Hypothesis 12 is concerned with the reasons why 
cephalosporins are not reviewed. The reasons listed were: 
1. Adequate equivalent already available:32% 
2. Adequate equivalent and minimal M.D. interest:28% 
3. Minimal M.D. interest:31% 
The results are summarized in Table 26. 
TAELP. 26 
REASONS WHY CEPHALOSPORINS 
ARE NOT PLANNED FOR REVIEW 
! ---------- ·----! ----------! ----------! -----·-----! 
! ! 1ST GEN. ! 2ND GEN.! 3RD GEN. ! 
! ---- ···----------! ----------! ----------!- ·--------! 
ADEQUATE 21 ! 17 16 ! 
! EQUIVALENT ! ! 
!---------------!--------- ·!----------!----------! 
ADEQ.EQUIV + ! 1.4 ! 18 18 
MIN. M.D. INT.! 
!---------------!----------!----------!----------! 
! MIN. H.D.INT.! 5 3i~ ! 34 ! 
!---------------!----------!----------!----------! 
df=4 X2=19.4 alpha= 0.05 p<O.OOl 
The figures in Table 26 indicate that there is a 
significant difference in the reasons why cephalosporins 
are not reviewed. Follow-up tests were conducted to 
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determine which generations were the cause of the 
significance. 
The post hoc test demonstrates that the first generation 
of cephalosporins differs from the other two generations 
of cephalosporins. Availability of an adequate equivalent 
is the primary reason why first generation cephalosporins 
are not reviewed. In four instances, bid contracts were 
used to decide between cephapirin and cephalothin. 
M.D. interest is rarely selected as a reason for a lack of 
planned review because these products have been available 
on the market for many years. Therefore, physicians likely 
J.J,;. j u d g e. t he s e d r u g s m o r e o n a t her ape u t i c e q u 1. v a 1 en t bas i s • 
\\'hen second and third generation cephalosporins are 
analyzed, minimal M.D interest is the most frequently 
selected reason. Physicians are many times satisfied with 
the antibiotics that are already available. Therefore, P&T 
committees may not be willing to evaluate those 
cephalosporins that are not already on formulary. 
Among the second generation cephalosporins, cefuroxime 
(25) and ceforanide (25) have the highest score for not 
being reviewed. Physicians do not seem to be interested by 
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the potential pharmacokinetic advantages offered by these 
two drugs. 
Among third generation cephalosporins, ceftriaxone (33) 
and ceftizoxime (16) have the highest number of no planned 
review responses. Ceftriaxone also had the highest number 
of planned review responses. Celtriaxone appears to divine 
health professionnals into two categories; those that are 
interested in the drug and those that have no interest. 
Testing .!!.Y.P.otheses 13 through 18 
Hypothese~ 13 through 18 are concerned with cephalosporin 
stocking:· The ranking order for formulary acceptance 
follows the order for cephalosporin stocking as determined 
b y a S p e a r m·a n Rank 0 r d e r c o r r e 1 at i o n t e s t . The r e s u 1 t s a r e 
indicated in Table 27. 
TABLE 27 
COMPARISON 
BETWEEN FORMULARY STATUS AND STOCKING STATUS 
!---------------!---- ·-----!-- -----------! 
!CEPHALOSPORIN ! STOCKED ! ON FORMULARY ! 
! ! # RK ! # RK ! 
!--- -----------!----------!--------------! 
! CEFAZOLIN ! 85 1 ! (!6 1 
!---------------!-- -------!----------- ·--! 
! CEFOXITIN ! ~2 2 l 82 2 ! 
!---------------!----------!--------------! 
! CEFOTAXIME ! 62 3 ! 57 3 ! 
!---------------!----------!--------------! 
! CEFOPERAZONE ! 56 4 ! 53 4 
!---------------!----------!--------------! 
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TABLE 27 (CONT.) 
COMPARISON 
BETWEEN FORMULARY STATUS AND STOCKING STATUS 
!---------------!----------!--------------! 
! CEFAMANDOLE ! 50 5 ! 48 5 ! 
!- ·-------------!----------!--------------! 
! CEFTIZOXIME ! 35 6 ! 34 6 ! 
!----- ·---------!----------!--------------! 
! CEFUROXIME ! 34 7 ! 25 10 ! 
r--------------'~-~-~--- ----------! ----------! -- ·------ -----! 
! CEFFNTCTD ! J 3 s-i-2/ B--;--------
1- -------------!----------!--------------! 
! CEPHALOTHIN ! 29 9 ! 31 7 
!-------- ------!----------!--------------! 
! MOXALACTAM ! 28 10 ! 26 9 ! 
!---------------!----------!--------- . --! 
! CEPHAPIRIN ! 16 11 ! 20 11 
!-- ------------!------- --!--- ----------1 
! ~EFORANIDE ! 13 12 ! 10 12 ! 
!---------------! ----------!--------- ·----! 
! CEFTRIAXONE ! 10 13 ! 7 13 ! 
!---------------!----------!--------------! 
S~earman coefficient = 0.96 alpha=O.OS 
The Spearman coefficient indica~es a high correlation 
between stocking and formulary acceptance (0.96). 
Cefuroxime~ moxalactam and cephalothifl have a different 
stock ranking compared to their formulary acceptance 
ranking. Special uses (e.g.specific diagnosis, trial use ) 
and restrictions of the drug utilization for only one 
service may explain the difference between the two 
rankings for these drugs. 
Next 1 the stocking status of cephalosporins was considered. 
The results are summarized in Table 28. 
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TABLE 28 
STOCKING STATUS OF CEPHALOSPORINS 
BY GENERATION 
!-------------!----------!----------!---------! 
! 1ST GEN. 2ND GEN.! 3RD GEN.! 
!-------------!----------!----------!---------! 
! STOCKED ! 130 (51%)!212(49.9%)!191 (45%)! 
!-------------!----------!----------!---------.! 
! NON STOCKED ! 125 (49%)!213(50.1%)!234 (55%)! 
!-------------!----------!----------!---------! 
!1-------------."GN FO Rl'fUI.;A-xy-!--rT/ ~--2T3 1 7/--j---------
!--- ---------!----------!----------!---------! 
df=2 X2=3.08 alpha=O.OS N.S. 
The figures in Table 28 demonstrate that there is no 
significan.t difference in the stocking of cephalosporins 
considererl by generation. Half of all first generation 
cephalosporins are stocked in our hospital sample. 
Cephalothin and ~ephapirin are stocked a lower level 
than their formulary acceptance. This is due to the bid 
contracts· generally indicative of two drugs. Cefazolin is 
:i.n stock in each hospital of our sample. 
Half of all second generation cephalosporins are st •eked 
in our hospital sample. Cefoxitin is the second generation 
cephalosporin most frequently stocked and has the same 
rate of formulary approval. On the other hand, 
cefamandole, cefonicid, ceforanide, and cefuroxime are 
stocked at a greater rate than their rate of formulary 
approval although the difference was shown not 
statistically significant. This difference might be 
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explained by the restriction of some cephalosporins to one 
hospital. Therefore, it is not necessary to admit these 
drugs onto the formulary. Trial use may also explain this 
phenomenon. When a drug is being used experimentally, it 
may be stocked prior to its formulary review. 
Of the third generation cephal.osporins, cefotaxime was the 
most frequently stocked third generation cephalosporin. 
Although cefotaxime· and ceftizoxime are considered 
therapeutic equivalents, the latter is not frequen.tly 
stocked (41.2% vs 73%). As with the second generation, 
third generation cephalosporins have a higher rate of 
stocking than 
stat i st:ically 
discrepancy is 
formulary 
significant). 
probably the 
generation. cephalosporins. 
accepta!o.ce (although not 
The reasons for this 
same as those of the second 
When the total stocking of cephalosporins was determined 
by hospitals, five cephalosporins is th~ most frequent 
number stocked. Six cephalosporins ranked second with only 
one less hospital. The results are summarized in Table 29. 
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TABLE 29 
NUMBER OF CEPHALOSPORINS STOCKED 
!-----------------!------------!-------------! 
! NUMBER OF ! RESPONDENTS PERCENTAGE ! 
CEPHALOSPORINS 
IN STOCK 
!---------- - ----!-------------!------------! 
5 ! 17 20% ! 
!-----------------!----------- -!---------- -! 
6 ! 16 ! 18. 8 r-,,--------
1--------- -------!-------------!------------! 
! 7 ! 14 ! 16.5% ! 
! -·------------------! . -----------! -------------I· 
! 4 ! 12 ! 14.1% ! 
------------------1-------------!------------J 
9 9 10.6% 
! ---------- -----!---- --------!------------! 
8 ! 6 77, ! 
!-----------------!-------------!--- -------! 
10 ! 3 3.5% 
!-----------------!-------------!------------! 
3 3 3.5% 
!---- ------ -----!-------------!------------! 
! 11 ! 2 ! 2.3% ! 
!-----------------!----- -------!------------! 
! 12 ! 1 ! 1.2% ! 
!-- ·---------------!-------------!------------! 
One is the most frequent number of first generation 
cephalospo~ins stocked representing 55.3% of the answers. 
Cefazolin is included in every combination of first 
generation cephalosporins. When two first generation 
cephalosporins are stocked, cefazolin and cephalothin is 
the favorite combination. Table 30 summarizes the results 
of first generation cephalosporin combinations. 
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TABLE 30 
1ST GENERATION CEPHALOSPORIN 
COMBINATIONS IN STOCK 
!--------------!------ ·------!--------------! -----------! 
! NUMBER OF ! CHOICE ! PERCENTAGE ! % OF TOTAL 
! 1ST GEN. 
! IN STOCK ! # % ! ! 
!---- ---------!- -----------!--------------!------------
! 1 (47) ~ CEFAZOLIN ! 47 100% ! 55.3% ! 
!==== ======= =!=============!==============!============! 
! 2 3 0 ! C E Flfz-m:n~~-T1 -u~"b-! :L 4----:-T%--------
! CEPHALOTHIN ! 
!-------------!--------------!------------! 
! CEFAZOLIN + ! 9 30% ! 10.6%· ! 
! CEPHAPIRIN 
!===============!=============!=============!===== ======! 
! 3 (8) ! CEFAZOLIN + ! 8 10 % ! 9.4% ! 
! ! CEPHALOTHIN+! ! 
! CEPHAPIRIN 
!--------------!-------------! --------!------------! 
Two, three and one represent the top three choices of 
second g~neration c~phalosporins stocked with 77.4% of the 
total hospitals. Cefoxitin is the most frequently stocked 
second generation cephalosporin. In seven cases, 
cefamandole and cefuroxime were stocked together although 
these pr~ducts are considered therapeutically equivalents. 
Cefoxitin and cefamandole are the most fr eq u·:·n t 
combinations despite articles about bacterial resistance 
due to cefamandole use. The different combinations of 
second generation cephalosporins are summarized in Table 
31. 
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TABLE 31 
COMBINATIONS OF 2ND GENERATION CEPHALOSPORINS 
IN STOCK 
!--------- ----!-------- ----!------------! ----------! 
! NUMBER OF CHOICE ! PERCENTAGE % OF TOTAL 
! 2ND GEN. 
! IN STOCK # # ! 
!--------------!-------------!-- --------!-------- ---! 
TWO 
! CEFOXITIN + ! 19 
! CEF AMAN )1/_.E 
57.6% ! 23.3% 
! ------------ ! --------- --.------- --·-- ~-------
! CEFOXITIN + ! 9 27.3% ! 10.6% ! 
! CEFUROXIME 
!--------- ---!------------! ------------! 
! CEFOXITIN + ! 5 15.1% ! 5.9% ! 
! CEFONICID 
!==============!=============!============!============--------!----
Combinations of two, one and three third generation 
cephalosporins represent 847% of all hospitals in our 
sample. Like the ~econd generation cephalosporins, the 
st~cking of third generation cephalosporins is less than 
formulary acceptance. The diversity of the single third 
generation cephalosporin reflects the heterogeneity of the 
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claAs as well as the hospitals in our sample. At that 
period of time(January-March 1 1985), ceftri8xone was never 
selected as the sole third generation cephalosporin. 
However, this product had only been out on the market for 
a few months at that time. The results of third generation 
cephalosporin combi;ations stocked in our hospital sample 
are summarized in Table 32. 
TABLE 32 
COMBINATIONS OF 3RD GENERATION CEPHALOSPORINS 
IN STOCK 
!---------- -----!--------------!------------!-----------! 
! NUMBER OF CHOICE ! PERCENTAGE ! % OF TOTAL! 
! 3RD Gf::N. 
! CEPHALOSPORINS # % 
,.,, ! -----------------! ---- ·---------! ------------! -----------! 
! ! CEFOTAXIME+ ! 12 42.8%! 14.1% 
! CEFOPERAZONE ! 
! . 
! ---------------! ·- ·-------·----! -----------! 
! CEFOPERAZONE+! 6 21.4%! 7. OS% ! 
! CE.F'l IZOX IME ! ! 
!--------------!----- - ----!-----------! 
! CEFOTAXINE + ! 6 21.47! 7.05% 
! MOXALACTAM 
!--------------!------------!-----------! 
! CEFOTAXIME ~ ! 2 7.1%! 2.!5% ! 
! CEFTIZOXIME 
!--------------!---- -------!-----------! 
! MOXALACTAM + ! 1 3.n%! 1.1% 
! CEFOPERAZONE ! 
! ---·--------- -! ------------! -----------! 
! CEFTIZOXIHE+ ! 1 3. 6%! 1.1% ! 
! CEFTRIAXONE ! 
! ================! === :==========! ============! == ========! 
l ! CEFOTAXIME ! 10 45.5%! 11.76% ! 
!--------------!- ----------!-----------! 
! CEFTIZOXIME 6 27.3%! 7.05% ! 
ONE !--------------! ·-----------!- ·---------! 
! C E F 0 PER A Z 0 N E ! 5 2 2 . 7!~ ! 5 . 8 8% ! 
! --------------! . ----------! ----------! 
MOXALACTAM ! 1 4.5%! 1.1% ! 
!================!==== =========!======= ====!===== ======! 
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TABLE 32 (CONT.) 
COMBINATIONS OF 3RD GENERATION CEPHALOSPORINS 
IN STOCK 
!----------------!--------------!---- -------!------ ----! 
'I'H~EE 
!-------
H J J? o th-e s e s 
influence 
! CEFOTAXIME + 9 
! MOXALACTAM + ! 
! CEFOPERAZONE ! 
42.8%! 10.6% 
!-------- -----!------------!---- ------! 
CEFOTAXIME + ! 6 27.3%! 7.05% ! 
! CEFOPERAZONE+! 
! CEFTIZOXIME 
!--------------!- ----------!-----------! 
! CEFOTAXIME + ! 4 19h ! 4.7% ! 
CEFOPERAZONE+! 
CEFTRIAXONE 
--~---------!------------!-----------! 
MOXALACTAM + ! 2 9.5% ! 2.35% ! 
CEFOPERAZONE+! 
CEFTIZOXIME 
-!--------------!------------!--- -------! 
15 through 18 were concerned with the 
of certain parameters on the stocking of 
cephal'osporins. As in previous analyses, the ~arameters 
selected were implementation of DRGs , the hospital 
teaching status and the hospital bedsize. The re&ults are 
summarized in Tables 33 through 45. 
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TABLE 13 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF CEPHALOSPORINS IN STOCK 
! ------------- -------!- ------! ---------! 
! NUMBER OF DRGS ! NO DRGS ! 
! CEPHALOSPORINS 
! IN STOCK 
!------------- -------!--------!--- ------! 
! FIVE 14 3 ! 
!- -------------------! ---- ---!---------! 
! SlX ! 10 ! 6 ! 
! -- -- ---------------! --------!- ·-------! 
! SEVE~,i ! 9 5 ! 
! ----------------------! --------·! -----··-----·! 
df=2 X2=1.89 alpha~~.OS N.S 
The figures: in Table 33 demonstrate that there is no 
sign~ficctnt-difference in the number of cephalosporins in 
stock due to the implementation of DRGs. 
TABLE 34 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF IST GENERATION CEPHALOSPORINS 
IN STOCK 
!---------------------!- -- ----!---------! 
NUMBER OF ! DRGS NO DP-GS 
! 1ST GENERATION 
! IN STOCK ! ! 
!---------------------!--------!--- -----! 
! ONE 30 17 ! 
!---------------------!--------!---------! 
! TWO 20 ! 10 
!---------------------!---- ---!---------! 
! THREE ! 4 4 ! 
!-----------------~---!--------!---------! 
df=2 X2=0.76 alpha:O.OS N.S 
Th~ figures in Table 34 demonstrate that there is no 
significant differe!tCe in the number of first generation 
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cepha~osporins in stock due to the implementation of 
DRGs. 
TABLE JS 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF 2ND GENERATION CEPHALOSPORINS 
IN STOCK 
!---------------------!--------! ---------! 
! NUMBER OF ! DRGS ! NO DRGS ! 
! 2ND GENERATION 
! IN STOCK 
!---------------------!--------!---------! 
! TWO 21 13 
!------~--------------!--------!---------! 
! T ;iRE E ! 1 0 ! 9 ! 
!---------------------!--------!---------! 
! OI'~E 10 ! 4 ! 
!---------------------!--------!---------! 
df=2 X2=1.27 a1pha=0.05 N.S 
Th~ figures in Table 35 demonstrate that there is no 
si;snifi·Ji'ant dj.fference in the nun;ber of second ger1eration 
cephalosporins in stock due to the implementation of 
DRGs. 
TABL:S 36 
INFLUENCE OF DRG IMPLEMENTATION 
ON NUMBER OF 3RD GENERATION CEPHALOSPORINS 
IN STOCK 
!--------- ·-----------!--------!---------! 
! NUMBER ! DRGS ! NO DRGS 
! OF 3RD GENERATION 
! IN STOCK 
!---------------------!--------!------- -! 
! TWO 21 ! 8 ! 
!---------------------!--------!---------! 
! 0'4E ! 13 9 
!---------------------!--------!---------! 
! TH ~EE 7 4 ! 
!------ ----------- --!--------!---------! 
df=2 X2=1.55 alpha=O.OS N.S. 
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The figures in Table 36 demonstrate that there is no 
significant difference in the number of third generation 
ce~halosporins in stock due to the implementation of 
D.P.G's. 
11------------"T'--'h"-e~____,c,._,h"-l"'"-·=--"s'-"quare test conducted tn ~etermine the influence 
of DRG imp.lemen ta ti on on the stockint; of all 
cephalosporins examined collectively as well as broken ~· 
down into generations did not demonstrate statistical 
signific"nce. This might be due to the fact that the 
nuu~er ;of cephalospori.ns in stock is not representative 
of the~quantity in terms of dollar percentage of overall 
invent O\r.y. Hosp.i. tals that have a large number of 
cephalosporins on stock may be highly concentrated in only 
several products while retaining th~ other products at a 
low inventory level for the purpose of special uses (e.g. 
trial use). Therefore, if DRG's were implemented, 
deletion of a few units of cephalosporin would have little 
or no effect on the hospital's avera 1 cost containm~nt 
measures. 
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TABLE 37 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF CEPHALOSPORINS IN STOCK 
!-- ---------------
! NUMBER OF 
! CEPHALOSPORINS 
! IN STOCK 
--!-------!--------! 
SMALL ! MEDIUM ! 
! <250 ! LARGE 
! )250 
!------------- -------!-- ----!------ ·-
! FIVE 12 ! 5 
!----- -----------~---!-------!--------! 
! SIX 9 7 
!------------ ·--------!-------!--------~ 
! SEVEN ! 5 9 ! 
!------------ ----- --!-------!--------! 
! FOUR ! 5 6 ! 
!---------- ----------!-------!--------! 
df=3 X2=4.11 alpha=0.05 N.S 
The fi g u r e s in Tab 1 e :J 7 d em on s t rat e t h a t L he r e i <: no 
sign~ficant difference in the number of cephalosporins in 
stock ~ue to hospital bedsize. 
TABLE 38 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF IST GENERATION CEPHALOSPORINS IN STOCK 
!--------- ---- ------!-------!--------! 
!NUMBER OF 
!1ST GENERATION 
!IN STOCK 
SMALL MEDIUM ! 
! <250 ! LARGE .! 
! )250 
!------------- .. ·-----!-------!---- ---! 
! ONE 22 24 
!---------------------!-------!--------! 
! TWO ! 18 ! 12 
!------------------- ·-!-------!--------! 
! THREE ! 3 4 
!---------------------!-------!-- -----! 
df=2 X2=1.32 alpha=0.05 2 CELLS<5.0 N.S 
df=l X2=1.08 alpha=0.05 N.S. 
The figu1·es in Table 38 demonstrat~ that there is no 
s i g n i f i cant d i f f e r e l t c e in the n 11mb e r o f f i r s t g e n e r at i o n 
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cephalosporins in stock due to ho~pital b~dsize. 
TABLE 39 
INFLUENCE OF HOSPITAL B~DSIZE 
ON NUMBER OF 2ND GENERATION CEPHALOSPORINS IN STOCK 
!-- ------------ -----!-------!--------! 
! NUMBER SMALL ! MEDIUM ! 
! OF 2ND GENERATION ! <250 ! LARGE 
~------------!-n~----sTo--cx i-;-z-ST;--!--------
1-------------- ------!-------! -------! 
! TWO ! 21 ! 12 
!---- ----------------!-------!--------! 
! THREE 11 7 
! ----·--·- ···--------- ---! ---------! -----·-·--! 
1 o~:E 1 5 ! 8 
!-------------- ------!-------!-- -----! 
! FOUR ! 4 ! 8 ! 
!---------------------!-------!--------! 
d£=3 X2=4.93 alpha=0.05 N.S. 
The figures in Table 39 demonstrate that there L.: no 
signif:i.J.L:ant difference in the number of second generation 
cephalosporins in stock due tu hospital bedsize. 
TABLE 40 
INFLUENCE OF HOSPITAL BEDSIZE 
ON NUMBER OF 3RD GENERATION CEPHALOSPORINS IN STOCK 
!-------------------
! NUMBER OF 
! 3RD GENERATION 
! IN STOCK 
-!---- --!-- -----! 
! SMALL MEDIUM ! 
! <250 ! LARGE 
! >250 
!-------- ------------!-------!--------! 
! TWO ! 17 11 
! --- ·-----------------! -------! --------! 
! ONE 13 ! 9 ! 
!---------------------!--- ·---!--------! 
! THREE 8 12 
!---------------------!-------!--------! 
! FOUR 3 8 
!------- ·-------------!- -----!---- ---! 
df=3 X2=5.07 alpha=0.05 N.S 
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' •. . ~· . 
The figures in Table 40 demonstrate that there is no 
significant difference in the number of third generation 
cephalosporins in stock due to hospital bedsize. 
Hospital bedsize does not seem to influence the number of 
cephalosporins in stock. The reasons are probably similar 
to those related to DRG status. The type of service 
available ~n the hospitals of our sample is likely a more 
relevant parameter concerning the number of cephalosporins 
in stock~ Those hospitals with a wide variety of services 
available. (i.e. ob./gyn., orthopedic surgery) are likely 
to hav·Q more varied requests for different cephalosporins. 
Again, this may not be indicative of the level of 
cephal;f:lsporins as a percentage of the total drug budget. 
TARLE 41 
INFLUENCE OF TEACHING STATUS 
ON NUMBER OF CEPHALOSPORINS IN STOCK 
!-------------------
! NUMBER OF 
! CEPHALOSPORINS 
! IN STOCK 
-!----------!--------------! 
TEACHING NON TEACHING 
!----------------------!----------!--------------! 
! FI ·,•E 3 14 
!---------------------!----------!--------------! 
! SIX 5 11 
!---------------------!----------!--------------! 
! SEVEN 6 8 
!---------------------!----------!--------------! 
! FOUR 4 ! 8 
!---------------------!----------!--------------! 
df=3 X2=2.38 alpha=O.OS N.S. 
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The fig,ires in Table 41 demonstrate that there is no 
significant difference in the number of cephalosporins in 
stock due to hospital teaching status. 
TABLE 42 
INFLUENCE OF TEACHING STATUS 
ON NUMBER OF 1ST GENERATION CEPHALOSPORINS IN STOCK 
!---------------------!----------!--------------! 
NUMBER OF ! TEACHING ! NON TEACHING ! 
! 1ST GENERATION 
! IN STOCK 
!---------------------!----------!--------------! 
! ONE 15 32 
!~---------------------!----------!--------------! 
! TWO 8 22 ! 
!---------------------!----------!--------------! 
! THREE 2 ! 3 ! 
!---------------------!----------!--------------! 
df=2 X2=0.47 alpha=0.05 2 Cells <5.0 N.S. 
df=1 X2=0.24 alpha=0.05 N.S. 
The f>i;g1Jres in Table 42 dem·.1nstrate that there is no 
significant difference in the number of first generation 
cephalosporins in stock due to hospital teaching status. 
TABLE 43 
INFLUENCE OF TEACHING STATUS 
ON NUMBER OF 2ND GENERATION CEPHALOSPORINS IN STOCK 
!------ ---------- ---!----- -- -!--------------! 
NUMBER OF TEACHING ! NON TEACHING 
! SECOND GENERATION 
! IN STOCK 
!--------- -----------!----------!--------------! 
! TWO 8 
!---------------- ----!----------!--------------! 
! THREE 7 10 
!------ --------- ------!----------!--------------! 
! ONE 5 9 
!---------------------!----------!--------------! 
df=2 X2=1.66 alpha=0.05 N.S. 
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The figures in Table 43 demonstrate that there is no 
significant difference in the number of second generation 
cephalosporins in stock due to hospital teaching status. 
TABLE 44 
INFLUENCE OF TEACHING STATUS 
ON NUMBER OF 3RD GENERATION CEPHALOSPORINS IN STOCK 
!---------------------!----------!-- -----------! 
! NUMBER.OF TEACHING NON TEACHING ! 
! 3RD GENERATION 
! IN STOCK 
!---------------------!----------!--------------! 
! TWO 8 ! 21 
!---------------------!----------!--------------! 
! ONE 5 ! 17 
-!---~-----------------!----------!--------------! 
! ~~HREE 8 ! 11 ! 
~-!---------------------!----------!--------------! 
! FOUR ! 4 ! 6 ! 
-·4--------- -----------!----------!--------------! 
~· df=3 X2=2.32 alpha=O.OS 1 cell<S.O N.S. 
The figur~s in Table 44 demonstrate that there is no 
significant difference in the number of third generation 
cephalosporins in stock due to hospital teaching status. 
Contrary to the results concerning formulary acceptance of 
cephalosporins, the number of cephalosporins in stock was 
not influenced by the hospital teaching status. This may 
be explained by the fact that in teaching hospitals the 
P&T Committees have access to a wider variety of 
experts(e.g. I.D. specialist) than their non-teaching 
coun :.,~rparts. This would lead to a more rigorous 
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pro~edure in getting a new drug approved to the hospital 
formulary. On the other hand, teaching hospitals are 
probably involved in experimentation leading to a higher 
level of stocking as compared to the drugs that have been 
accepted on formulary. 
RESULTS AND DISCUSSION 
Hypotheses 1 through 3 were designed to study the 
formulary approval of cephalosporins. The analysis 
reveal~d that the first generation of cephalosporins is 
more fr~quently accepted onto hospital formularies than 
the setrond and third generation cephalosporins. Despite 
the f:act. ·that the current literature describes the 
restricted formulary status as a useful tool to control 
the use of antibiotics, the full approval status was the 
most common status once a drug was accepted onto the 
formulary. Third generation cephalosporin demonstrated a 
higher rate of restricted approval status for the 
identical reasons (ID. consultation and specific 
diagnosis) as the second generation cephalosporins. 
Four cephalosporins (cefazolin, cefoxitin, cefotaxime and 
cefoperazone) represented over half of the total number of 
cephalosporins that received formulary acceptance in our 
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sample. Cefazolin was admitted on each formulary of the 85 
hospitals cons~dered. In terms of the number of 
cephalosporins accepted onto hospital formularies, four, 
five and six cephalosporins are the most frequent number 
of cephalosporins admitted. These three 
sample. 
numbers 
represented 58% of our hospital When 
cephalosporins were considered by generation, one first 
generation, two sec.ond :generation and two third generation 
cephalosporins 
cephalosporin 
confirms the 
were the most frequent numbers 
products admitted on formulary. 
trend to limit the formulary acceptance 
of 
This 
of 
cephalQ~porins particularly in the first generation. 
The rea~ons for the non-formulary status of cephalosporins 
was of interest in testing hypotheses 7 through 12. The 
date of marketing was shown to be moderately correlated to 
the formulary status. After a product enters the market, 
formulary acceptance follows as a function of time. 
Frequently, the product is tested by physicians within a 
hospital and, through an acculturation process, becomes 
'accepted as being efficacious. The advantages of new 
products (e.g. pharmacokinetics, dosing schedule ) did not 
seem to stimulate the formulary acceptance of 
cephalosporins. When the non-formulary status was 
analyzed, the first generation cephalosporins had the 
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lo~est frequency of planned review status. This appears to 
be due to the fact that these drugs have been 
available for a long time 
have been recently marketed. 
and 
The 
that no 
main 
new products 
reasons for 
formulary rejection of cephalosporins were due to high 
co<:Jt :J.nd the availability of therapeutic equivalents. High 
cost alQne was a more predominant factor among the first 
generation cephalosporins. Side-effects was a signifi~~nt 
c.au·c;e of formulary rejection in the case of the third 
generation cephalosporins. This was mostly due to the 
bleedi~g problems reported with moxalactam therapy. The 
main reasons for not reviewing a drug was different 
according to the generation considered. The availability 
of theTapeutic equivalent was the major reason for the 
first gen~ration cephalosporins. This confirms that the 
notion of interchangeability that has been reported in the 
literature. Second and third generation cephalosporins 
were not reviewed for formulary acceptance primarily 
because of minimal M.D. interest. 
Hypotheses 13 through 18 were concerned with the stock~ng 
of cephalosporins. Cefazolin, cefoxitin, cefotaxime and 
cefoperazone were the most frequ~nt1y products in stock. 
The formulary ranking correlates with the stocking. This 
demonstrates that the formulary acceptance of a drug may 
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imply the stocking of this drug. Five, six and seven 
cephalosporins were the most frequent numbers of 
cephalosporins in stock. When the cephalosporins are 
divided into generations, one first generation, 2 second 
and two third generation were the most common numbers of 
cephalosporins in stock. This distribution is similar to 
the number of cephalosporins admitted on formulary. 
However, when the relationship between the ·number· of 
cephalosporins in stock was compared to the number of 
cephalospurins admi~ted on formulary, the two variables 
demons:t.rated only moderate correlation. This may be due to 
the stoeking of drugs reserved for trial use or restricted 
to onec~ervice. When the total number of cephalosporins in 
stock was analyzed relative to DRG implementation, 
" 
hospital teaching status and hospital bedsize, no 
significant. differences were identified. The numbe.r of 
cephalospor~ns in stock may not be directly related to the 
proportion of the drug budget devoted to cephalosporins. 
Future research might include inventory cost as a variable 
to be tested against the three aforementioned parameters. 
This study was conducted during the first quarter of 1985. 
Further research may focus on the changes in formulary 
status of the drugs studied in this project as well as new 
cephalosporins that have entered the marketplace since 
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early 1985. In 1987, DRG's will be fully implented across 
the United States. This situation may eventually have a 
profound effect on the process of accepting expensive 
antibiotics to ho~pital formularies. Even if these 
products are accepted, their availability will likely be 
subject to tight restrictions due to cost containment 
incentives that have. become prevalent throughout .our 
health care .syste.m. 
8> 
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